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PREHOSPITAL TROPONIN TESTING PROTOCOL FOR ACCELERATED 
DIAGNOSIS AND EARLY INTERVENTION IN CHEST PAIN PATIENTS 
 
Ronald D. Meador 
DNP Scholarly Project Chair: Sandra Peterson, DNP 
The University of Texas at Tyler 
May 2019 
 Non-ST elevation acute coronary syndromes (NSTE-ACS) have significant 
morbidity and mortality rates despite the progress made in diagnosis and management 
and represent a significant public health burden in the United States.  Lengthy diagnostic 
algorithms contribute to emergency department over-crowding, increased health care 
costs, and adverse patient outcomes.  A troponin assay instituted earlier in the diagnostic 
pathway of patients with chest pain suspected of NSTE-ACS will reduce time to 
definitive diagnosis and medical intervention.  This will improve patient outcomes, 
decrease emergency department crowding through improved ED workflow, and reduce 
the economic burden.  The Star Model of Knowledge Transformation was used to guide 
an understanding of the cycles, nature, and characteristics of knowledge of NSTE-ACS, 
organize previous and current concepts of improving care, and provided the framework to 
guide design, implementation, evaluation and sustainability.  The Prehospital Troponin 
Testing Protocol (PHTTP) instituted a point-of-care troponin assay in the ambulances of 
the Plainview Fire-EMS department and used this value in an accelerated diagnostic 
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pathway in the Covenant Plainview Emergency Department.  The PHTTP reduced the 
time to first troponin from 79 minutes (1.32 hours) to 22 minutes (0.37 hours) and time to 
disposition of patients from 191.00 minutes (3.18 hour) to 150.04 minutes (2.50 hours).  
Time to first troponin was reduced by 47.00 minutes (0.78 hours) and length of stay was 
reduced by 40.96 minutes (0.67 hours). The prehospital scene time was increased by 1 
minute which was not statistically significant. 
 Keywords: non-ST segment elevation acute coronary syndrome, prehospital 
troponin, accelerated diagnostic pathway, and emergency department overcrowding. 
 
  
 
 
 
 
 
Chapter 1 
Development of the Clinical Question and Problem Identification  
Introduction 
 The Prehospital Troponin Testing Protocol (PHTTP) for Accelerated Diagnosis 
and Early Intervention in Chest Pain Patients is an inter-professional, collaborative, 
biphasic evidenced-based practice implementation project (EPIP).  The PHTTP is inter-
professional as it requires the collaborative practice of prehospital personnel (Emergency 
Medical Technicians and Paramedics) and clinical emergency medicine staff (nurses, 
advanced practice providers, and physicians).  The PHTTP has two distinct phases: the 
prehospital phase and the clinical emergency medicine phase with the collective goal of 
improving patient outcomes and improving ED workflow.  This protocol is designed to 
concurrently improve patient outcomes and emergency department workflow without a 
significant increase in prehospital scene times.  These improvements are accomplished 
through the utilization of a prehospital point-of-care troponin assay incorporated into an 
accelerated diagnostic algorithm for patients with chest pain who present to the 
emergency department (ED) via emergency medical services (EMS). 
Background and Significance 
 Non-ST Elevation Acute Coronary Syndrome(NSTE-ACS) is one of three acute 
coronary syndromes (ACS) without significant ST segment elevations demonstrated on 
the electrocardiogram (ECG).  NSTE-ACS is caused by a partial occlusion of a coronary 
artery.  This patient population forms approximately two-thirds of all hospital admissions 
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for ACS in the United States each year and is associated with an in-hospital mortality of 
5% (Bob-Manual, 2017).  According to the American College of Cardiology/American 
Heart Association (ACC/AHA), despite the progress made in recent years in the 
diagnosis and management of NSTE-ACS, the rate of morbidity remains high and the 
rate of mortality is significant (Rodriguez, 2016) (see Appendix A).  Previous research 
demonstrates the utilization of a prehospital testing protocol will reduce the public health 
burden of NSTE-ACS by decreasing the time required for final diagnosis; and utilization 
of early interventional strategies, and thus decreasing the percentage of major adverse 
cardiac events (MACE) over time.   
 In the United States (US), an NSTE-ACS event occurs every 25 seconds and an 
NSTE-ACS-related death occurs every minute (Amsterdam, 2014).  Further, 9-19% of 
patients who experience an NSTE-ACS event die in the first six months after diagnosis 
and half of these deaths occur within the first 30 days (Amsterdam, 2014).  There are two 
types of ACS events: (1) NSTE-ACS, and (2) unstable angina (UA).  The economic 
impact of all NSTE-ACS-related causes of morbidity and mortality is estimated to $141 
trillion annually (Vendanthon, 2014). Amsterdam (2014) estimated that more than 
780,000 individuals will have an ACS event annually and approximately 71% of them 
will be diagnosed as NSTE-ACS.  The diagnosis and treatment of NSTE-ACS represents 
a significant public health burden in the United States (Amsterdam, 2014).  Emergency 
departments (ED) in the US are currently in crisis due to overcrowding and diagnostic 
delays (Barish, 2012).  The current utilization of lengthy NSTE-ACS diagnostic 
algorithms contributes to these extended lengths of stay (LOS), poor ED workflow, and 
the overcrowding (Barish, 2012).  Cullen (2013) found prolonged assessment of patients 
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with chest pain who were suspected of ACS; contributed to overcrowding, increased 
costs, and adverse patient outcomes, including increased incidence of MACE.  As ED 
overcrowding adversely impacts patient morbidity and mortality, measures to decrease 
ED LOS and improve ED workflow have been advocated (Meek, 2016). 
 Amsterdam (2014) demonstrated that a delay in the diagnosis of NSTE-ACS is 
associated with increases in morbidity and mortality from MACE.  Darling (2013) 
demonstrated that patients with acute myocardial infarction (AMI) experienced a better 
post-discharge prognosis than those with NSTE-ACS.  The factors associated with 
increased mortality for each of these patient groups were slightly distinct.  Therefore, 
NSTE-ACS events represent a significant economic and health burden in the US and 
much of this burden is due to the time required to diagnose and initiate appropriate 
treatments using current diagnostic algorithms. 
 The incidence of NSTE-ACS increases significantly after age 18 (Amsterdam, 
2014).  The American Heart Association (AHA) reported the age range for NSTE-ACS 
events in the United States is 56-79 years with a median age of 68.  The ratio of males to 
females is 3:2. NSTE-ACS is more frequent in African Americans than Caucasians.  The 
rate of NSTE-ACS also increases proportionally with the number of comorbidities 
(Amsterdam, 2014).  Patients at greater risk for NSTE-ACS events present either the 
following major risk factors or a combination of them: high-serum cholesterol, 
hypertension, diabetes mellitus, obesity, and smoking. Moreover, 25% of NSTE-ACS 
patients have diabetes (Amsterdam, 2014).   
 An early invasive treatment strategy can postpone the occurrence of death or next 
acute coronary event by an average of 18 months and readmission to the hospital for 
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ischemic heart disease by 37 months as compared to a non-invasive strategy in patients 
with NSTE-ACS (Wallentin, 2016).  Therefore, patients with longer transport time to a 
healthcare facility have increased risk of morbidity and mortality from MACE events 
than urban patients with shorter transport time.  
 The American College of Cardiology/American Heart Association, in their most 
current guidelines published in 2014, recommend that the utilization of early invasive 
strategies (EIS) is likely to improve patient outcomes (Khera, 2014).  Morrow (2001) 
demonstrated that patients with clinically documented NSTE-ACS derive significant 
clinical benefit from EIS.  Serial cardiac troponins should be obtained upon presentation 
of chest pain in patients after 90 minutes to two hours if using high-sensitivity troponin 
assays, and three hours later, if using non-high-sensitivity troponin assays (Amsterdam, 
2014).  This 90-minute to 3-hour algorithm contributes to the ED LOS, time required for 
definitive diagnosis, and associated costs (Luca, 2016).  Khera (2014) in a meta-analysis 
of randomized, controlled trials demonstrated a consistent benefit in the utilization of EIS 
in the setting of NSTE-ACS, especially in setting high-risk populations. They further 
concluded that the earlier these strategies are employed, the better the patient outcomes 
are.  Layfield (2014), in a systematic review, found that serial cardiac troponin sampling 
with one sample at presentation and at least one additional sample collected two hours 
later was necessary to identify a rise or fall in the troponin level.  Testing with high-
sensitivity cardiac troponin assays without other biomarkers at presentation and then at 
90 minutes to two hours is the current testing algorithm for most accurate and timely 
NSTE-ACS diagnosis.   Therefore, the PHTTP can decrease the diagnostic interval of 
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NSTE-ACS and initiate EIS sooner by obtaining the first troponin value in the ambulance 
instead of waiting until the patient arrives in the ED and delaying the diagnosis.  
 Troponin is a regulatory protein complex of striated cardiac and skeletal 
muscle.  The troponin complex is divided into three subunits: Troponin C (TnC), 
Troponin I (TnI), and Troponin T (TnT).   TnC is tissue-specific to skeletal muscle 
damage and TnI and TnT are tissue-specific to myocardial damage (Vasile, 2009).  TnI 
and TnT are the standard cardiac diagnostic biomarkers referred to as cTnI and cTnT, 
respectively (Mahajan, 2011).  Free forms of cTnI are released in the early stages of 
ischemia and bound forms are released from degradation as ischemia progresses (Vasile, 
2009).  Therefore, the PHTTP will utilize cTnI as the biomarker because of its increased 
specificity to myocardial ischemia. 
 The development of sensitive cardiac Troponin I (cTnI) assays permits the 
detection of lower concentrations of cTnI earlier as it begins to rise within three to four 
hours after the onset of myocardial injury (Sherwood, 2014).  Sherwood (2014) 
demonstrated that the use of cTnI assays facilitates earlier diagnosis of NSTE-ACS and 
improves risk stratification.  Borna (2016) demonstrated that cTnI testing was a superior 
biomarker to diagnose NSTE-ACS within three hours of the patients presenting to the ED 
with chest pain.  POC testing equipment has provided portability and reliability to 
troponin evaluation which provides a stable platform to utilize in the prehospital setting.  
Therefore, the use of prehospital cTnI POC testing has the potential to reduce the 
diagnostic timeframe and streamline the care of NSTE-ACS patients beginning earlier in 
the treatment pathway.  This reduction in diagnostic time will facilitate the utilization of 
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EIS and over time reduce the impact of MACE events following the diagnosis of NSTE-
ACS. 
 Roffi (2015) reported chest discomfort as the leading symptom that initiates the 
diagnostic and therapeutic cascade in patients with suspected ACS.  Patients reporting 
chest pain frequently use emergency medical services (EMS) for transport to the ED.  For 
patients reporting chest pain due to NSTE-ACS, in the prehospital setting, current clinical 
guidelines offer in-hospital risk stratification and management as opposed to 
straightforward prehospital strategy for diagnosis, medication regimen, and logistics 
(Ishak, 2014).  
 Stengaard (2013) validated the feasibility of using prehospital troponin 
quantitative POC cardiac troponin testing and its capacity to predict mortality.  They 
additionally demonstrated the potential to accelerate triage and diagnosis of NSTE-ACS 
patients using POC troponin testing is feasible.  Stengaard also found that the diagnosis 
of NSTE-ACS in the prehospital phase impacts the mode of revascularization, is 
associated with earlier revascularization, and results in shorter hospital stays and 
improved long term outcomes.  Venturini (2013) found that there was no statistical 
difference between prehospital and ED troponin results, thus concluding that POC-cTn is 
a stable and accurate biomarker testing platform (see Appendix B).  Despite being used in 
a moving ambulance, POC testing reliably provided accurate results of troponin assays as 
compared to the results of those performed in the ED.   Ezekowitz (2015) found that 
prehospital POC-troponin testing decreased the time from first medical contact (FMC) to 
final disposition in the ED by 0.29 hours.  Ezekowitz additionally postulated that this 
0.29-hour reduction time to final diagnosis within an urban setting with short transport 
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times could be applied in a rural setting with long transport times and the effect could be 
potentially magnified.  Ezekowitz (2015) and Venturini (2013) demonstrated that 
prehospital troponin is a reliable diagnostic platform and has the potential to reduce 
diagnostic time for NSTE-ACS patients.  The utilization of prehospital personnel to use 
POC devices to measure troponin levels during transport of patients to the ED may result 
in earlier diagnosis of NSTE-ACS (Venturini, 2013).  Patel (2012) determined average 
ground EMS transport times of 43.3 minutes (urban) and 57.6 minutes (rural).  Sorenson 
(2011) indicated that implementation of quantitative prehospital troponin testing by 
paramedics is feasible and effective.  Therefore, prehospital POC testing can expedite the 
diagnosis of NSTE-ACS by reducing the two-hour ED diagnostic window.  
 Conclusions: 1) According to Darling (2013), NSTE-ACS patients have a 16.4% 
higher incidence of MACE than AMI patients, 2) high-sensitivity troponin is the 
biomarker of choice in the diagnosis of NSTE-ACS, 3) accelerated diagnostic pathways 
using high-sensitivity troponin testing can reduce the time to diagnosis of NSTE-ACS, 4) 
prehospital troponin testing can reduce the prevalence of MACE events by reducing time 
by utilizing EIS, 5) the use of prehospital troponin testing along with an accelerated 
diagnostic protocol can further reduce diagnostic time by as much as 0.29 hours in the 
urban setting according Ezekowitz (2015) and potentially higher in the rural setting, 6) 
treatment delays from current diagnostic pathways results in greater MACE for NSTE-
ACS patients than AMI patients (see Appendix B).  The use of prehospital troponin 
testing with an accelerated diagnostic protocol can further reduce diagnostic time by as 
much as 0.29 hours in the urban setting and potentially higher in the rural setting 
(Ezekowitz, 2015).  Therefore, prehospital POC troponin testing can decrease the 
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diagnosing time of NSTE-ACS by a minimum of 0.29 hours and concomitantly reduce 
the incidence of MACE through utilization of NSTE-ACS patients from 12% to 8.9% 
MACE at 10 months according to Cantor (2005).  In summary, based on the background 
evidence referenced, NSTE-ACS represent a significant public health burden and the 
utilization of a PHTTP can reduce this burden.  
Development of the Clinical Question/Problem – PICOT Question 
 In patients with chest pain suspected of non-ST segments acute coronary 
syndromes (P), how does prehospital troponin testing (I), compared to no prehospital 
troponin testing affect time to diagnosis of acute coronary syndrome (O1) and utilization 
of early interventional strategies (O2), associated morbidities (O3), major adverse cardiac 
events (04), ED workflow and overcrowding (O5), and reduce economic burden (O6) 
over a thirty-day period (T)? 
The Star Model of Knowledge Transformation 
 The Star Model of Knowledge Transformation is a model for understanding the 
cycles, nature, and characteristics of knowledge that are used in various aspects of 
evidence-based practice (Stevens, 2012).  The Star Model organizes previous and current 
concepts of improving care and provides the framework to organize evidence-based 
practice (EBP) processes as follows: Star Point 1 (Discovery Research): This step 
presents information from the studies in the Evidence Table.  Star Point 2 (Evidence 
Summary): Evidence summary is the first unique step in EBP and its purpose is to 
synthesize the body or research knowledge into a compact, meaningful statement of the 
state of the science.  This stage reduces large quantities of information into a manageable 
form to establish generalizability across participants, setting, treatment variations, and 
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study design.  Star Point 3 (Translation to Guidelines): The goal of the translation stage is 
to provide a useful and relevant package of summarized evidence to clinicians and clients 
in a form that suits the time, cost, and care standard.  Based on this package of evidence, 
recommendations are made as clinical practice guidelines and may represent clinical 
pathway, protocols, and algorithms.  Star Point 4 (Practice Integrations): This step 
involves changing both individual and organizational practices through formal and 
informal channels.  Star Point 5 (Process, Outcome Evaluation): This is the final stage in 
knowledge translation where the impact of the EBP project on patient health outcomes, 
provider and patient satisfaction, efficacy, efficiency, economic analysis, and health 
status impact is evaluated (Stevens, 2012).  The Star Model provides a systematic 
framework for the initiation of a PHTTP for an EBP change based on the best available 
evidence. 
Systematic Search for Evidence Process and Results 
 A systematic search was conducted using three primary electronic databases: 1) 
the Cumulative Index to Nursing and Allied Health (CINAHL), 2) the Cochrane 
Database of Systematic Reviews (CDSR) and 3) PubMed.  Three major searches were 
conducted in the CINAHL database: keyword, title, and subject heading.  Two major 
searches were conducted in the Cochrane Database: combination (title/abstract/keyword) 
and keyword.  Five major searches were performed in PubMed: MeSH terms, MeSH 
major topics, MeSH title title/abstract, and title (see Appendix C). 
 The search across all databases was performed with terms from the PICOT 
question and their major synonyms, acronyms, coined phrases, and brand names.  These 
terms include the following: acute coronary syndromes, ACS, non-ST segment elevation 
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myocardial infarction, NSTEMI, non-ST segment elevation acute coronary syndrome, 
NSTE-ACS, troponin, high sensitivity troponin, point of care troponin, prehospital 
troponin, early invasive strategies, and EIS.  The only limitations implemented in the 
searches were English and humans.  Appendix C demonstrates the systematic search 
through all three databases using the terms previously listed from the PICOT question.  
 Articles containing any of the following variables were deemed eligible for 
review related to the PICOT question: prehospital troponin testing, POC troponin testing, 
diagnostic windows for ACS diagnosis, NSTE-ACS morbidity and mortality, early EIS 
for ACS, accelerated diagnostic protocols for diagnosis of ACS, cardiac biomarkers for 
diagnosis of ACS, PCI strategies for ACS, treatment of hospitalized patients diagnosed 
with ACS, effectiveness of thrombolytics and percutaneous coronary intervention in 
ACS, MACE scoring of ACS patients, reliability of prehospital POC systems, and 
diagnostic delays in ACS patients.  Articles were excluded if they contained the 
following variables: less than eighteen years of age, chest pain of non-cardiac origin, 
symptoms greater than 12 hours from onset, AMI without mention of NSTE-ACS, ACS 
without specific mention of NSTE-ACS, diagnostic pathways exceeding two hours, 
diagnosis without mention of troponin, prehospital transport via aeromedical services, in-
patient management without mention of emergency department treatment, and articles 
without mention of outcomes related to ACS patients.  
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Figure 1. Systematic Search Results Flowchart 
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Conclusion 
 NSTE-ACS events represent a significant public health burden to not only the 
patients but also the health care systems that they access to seek care.  NSTE-ACS 
events, despite advances in diagnostic pathways and interventional strategies, continue to 
have high morbidity and mortality rate than STE-ACS events.  EMS are often the first 
medical providers who contact chest pain patients and represent an untapped resource to 
make improvements in patient outcomes using new technologies.  These medical 
providers in the early assessment of cardiac biomarkers are an underutilized system to 
improve the outcomes of patients and the overall health care system. 
  
 
 
 
 
 
Chapter 2 
Critical Appraisal of the Evidence, Model, and Plan 
Appraisal of Evidence 
 The scholarly articles obtained from the systematic search discussed in Chapter 
One were evaluated using the critical appraisal process to identify the strengths and 
weaknesses to assess the usefulness and validity of the research findings.  Initially, a 
General Appraisal Overview (GAO) was completed, followed by a Rapid Critical 
Appraisal (RCA) to assess validity, reliability, and applicability.  One article was 
excluded after completing the critical appraisal process as the study was incomplete and 
therefore the validity of proposed outcomes could not be validated, thus impairing its 
reliability and applicability to this project.  The remaining 10 articles were determined to 
have conclusions adequately supported by the data presented and data evaluated had 
validity, reliability, and applicability to this project. 
 There were no ethical concerns resulting in the exclusion of any additional 
studies.  All studies demonstrated (where applicable) that 1) Respect for Autonomy—
participants freely participated of independent choice without evidence of coercion and 
informed consent was obtained from all participants, 2) Non-maleficence—there was no 
harm or the least possible harm to reach a beneficial outcome, 3) Beneficence—
interventions are to benefit individuals outcomes, 4) Justice—fair selection of study 
participants without bias, 5) Equipoise—genuine uncertainty when assigning patients to 
treatment arms, 6) bias free trial in case of industry funded research, and 7) appropriate 
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Institutional Review Board (IRB) approval was acquired or waived as required. 
 Further, 36 articles were identified from the search of CINAHL, CDSR, and 
PubMed and the Abilene Christian University Library in Abilene, Texas that initially met 
criteria of the PICOT question.  Additionally, two non-full text and three duplicate 
records were removed, yielding 31 articles for review using inclusion and exclusion 
criteria as previously discussed. After applying the inclusion/exclusion criteria, 20 
articles were excluded.  One article was removed article during the critical appraisal 
process as the study was incomplete at the time of publication and therefore reliable 
outcome data was not present.  Therefore, the final yield was 10 articles included in the 
body of evidence (36 – 2 – 3 – 20 – 1 = 10). 
Evaluation of the Body of Evidence 
 Ten studies were used to provide the body of evidence to address the components 
of the PICOT question.  These studies supported the assertion that the implementation of 
a high-sensitivity troponin testing protocol can reduce the time to final diagnosis of 
NSTE-ACS, concomitantly reduce the time to EIS and therefore reduce the incidence of 
MACE and improve outcomes of patients with chest pain encountered in out-of-hospital 
setting.  The following components of the PICOT question will be validated with the 
evidence compiled: 1) POC cTnI is the assay of choice for this implementation, 2) the 
appropriate diagnostic window is 90 minutes to two hours, 3) utilization of prehospital 
POC cTnI is accurate and reliable, and 4) reduction in the time from first medical contact 
to diagnosis of NSTE-ACS in patients with chest pain reduces the duration of the 
utilization of EIS, and 5) the utilization of EIS earlier in the diagnostic pathway of NSTE-
ACS patients reduces MACE and improves patient outcomes. 
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 The Study Methodology Synthesis Table in Appendix D demonstrates that cTnI is 
the assay of choice to utilize in the project implementation.  Studies of Vasile (2009) and 
Sherwood (2014) demonstrated that cTnI assays permits the detection of lower 
concentrations of cTnI earlier than cTnT as cTnI begins to rise within three to four hours 
after the onset of myocardial injury.  The 12 studies listed in the Study Methodology 
Synthesis Table in Appendix E demonstrated that the use of prehospital POC cTnI is a 
statistically reliable assay method to use on patients with chest pain.  The 90 minute to 
two hour diagnostic testing window was an effective interval to make accurate diagnostic 
decisions regarding patients with chest pain.  Therefore, the included studies support the 
assertion that the use of prehospital POC cTnI is a reliable methodology to diagnose 
NSTE-ACS in patients encountered outside the hospital ED. 
 The Outcome Synthesis Table in Appendix F demonstrates the evidence reviewed 
supports the PICOT question assertion that reducing the time to diagnosis of NSTE-ACS 
improves patient outcomes.  The studies included demonstrate that a prehospital POC 
cTnI protocol can reduce the time to diagnosis of NSTE-ACS in patients with chest pain 
encountered outside the ED setting by reducing the time from first medical contact 
(FMC) to first troponin (T1).  Ezekowitz (2015) demonstrated that prehospital POC-
Troponin testing decreased the time from FMC to final disposition in the ED by 0.29 
hours.  Therefore, evidence suggests that the initiation of a prehospital POC cTnI testing 
protocol will reduce the duration of diagnosis of NSTE-ACS in patients with chest pain 
suspected of NSTE-ACS. 
 The Outcome Synthesis Table in Appendix F additionally demonstrates that as the 
time from FMC to T1 is decreased, the remainder of the time variables are concomitantly 
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reduced.  The evidence demonstrates that if FMC to T1 is reduced then T1 to T2 is 
reduced, T2 to diagnosis is reduced, diagnosis to EIS is reduced.  As the time from FMC 
to EIS is reduced, the evidence demonstrates that MACE is reduced.  Therefore, the 
evidence demonstrates that prehospital POC cTnI testing reduces time from FMC to 
diagnosis and EIS. 
Synthesis and Recommendation Based of the Body of Evidence 
 Institute a pre-hospital POC cTnI testing EPIP using an accelerated diagnostic 
protocol to reduce to LOS of chest pain patients that present to the ED via EMS with 
complaints of chest pain of suspected NSTE-ACS.  The evidence demonstrated that 
prehospital POC troponin testing is a valid and reliable method which has been 
successful in reducing the time to disposition in a large urban emergency department.  
This reduction in disposition time can reduce ED LOS, improve ED workflow and reduce 
ED overcrowding, and reduce the morbidity and mortality rate of NSTE-ACS 
occurrences longitudinally. 
Proposed Evidence-based Implementation Project and Operationalization 
 The Theory of Planned Change will be used as a conceptual framework to guide 
the evidence-based practice (EBP) change to initiate prehospital troponin testing with the 
goal of reducing the morbidity and mortality of chest pain patient, suspected of NSTE-
ACS, encountered outside the hospital and time to final disposition (see Appendix 
G).  Lippitt, Watson, and Westley’s (1958) theory of Planned Change is a seven-step 
framework focusing on the role of the change agent throughout the evolution of a change.  
Lippitt’s Change Theory (1958) is based on the introduction of an external change agent 
designing a program to effect change.  This theory focuses on the role and responsibility 
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of the change agent where there is a continuous exchange of information throughout the 
process.  The seven-steps are as follows: 1) Diagnose the problem, 2) Assess the 
motivation and capacity for change, 3) Assess the resources and motivation of the change 
agent, 4) Choose progressive change objects, 5) Select and clearly understand the role of 
the change agents for clear expectations, 6) Maintain the change, and 7) Gradually 
terminate from the helping relationship.  The seven steps of this theoretical framework 
will be utilized in conducting an EBP change project regarding the NSTE-ACS all-cause 
mortality.  Planned change theory in nursing is an important process ensuring the best 
practices are utilized to meet the advancing needs of the health care system and the 
patients it serves.  Planned change is a purposeful, calculated, and collaborative effort led 
by a change agent to effect a positive change within a specific system (Roussel, 2006). 
 Application of the seven-steps of the TCP: 1) Problem: High > 30 day post 
NSTE-ACS mortality (see Appendix G)/ED overcrowding, 2) Assess Motivation: Are the 
EMS systems and ED willing to make a change?  Are the EMS and ED systems willing 
to collaborate with each other? Is the return on investment substantial enough to justify 
the initial cost?  Is the ED system willing to accept a troponin value obtained outside of 
the ED?  Is the cardiology service or hospitalist service willing to accept a patient with a 
diagnosis of NSTE-ACS with an out-of-hospital troponin? 3) Change Agent and 
Motivation: Doctorate of Nursing Practice (DNP)-prepared nurse with emergency 
medical experience in both prehospital and ED setting with the best evidence to 
demonstrate that by reducing the time from T1 to T2, through the use of a prehospital 
troponin protocol, that patient outcomes will be improved, 4) Select Progressive Change 
Objects: Initiate prehospital troponin testing protocol that will systematically reduce the 
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variables in NSTE-ACS patients (see Appendix G), 5) Choose a Change Agent Role: 
DNP collaborative relationship with inter and intra-professional components, 6) Maintain 
Change: Assess data (variables listed in Appendix G), re-evaluate (are times decreasing 
as expected?) and adapt (if times are not decreasing why are they not and what 
intervention needs to be made to improve?), and sustain change (if times are decreasing 
and therefore patient outcomes are improving then distribute data to stakeholders for 
sustainability), and 7) Termination of Helping Relationship: DNP completes change and 
searches for new problems (see Appendix G). 
 The PHTTP will initiate and evaluate the effectiveness of a prehospital, POC 
troponin testing protocol.  This project aims to reduce the burden of greater than thirty-
day MACE of patients diagnosed with NSTE-ACS.  Based on the evidence, the time to 
final disposition of chest pain patients encountered outside the hospital is expected to be 
reduced by at least 0.29 hours.  In addition, the initiation of EIS earlier is expected to 
reduce the MACE in NSTE-ACS patients (see Appendix F).  These results will be 
evaluated to determine if this project was as effective as hypothesized in the literature. 
Conclusion 
 Based on the synthesis of the best available evidence the implementation of a 
prehospital POC cTnI protocol will reduce the time from FMC to disposition of patients 
with suspected NSTE-ACS.  This reduction in diagnostic time will allow for initiation of 
EIS earlier in the treatment pathway of NSTE-ACS patient and improve outcomes by 
reducing the incidence of MACE as previously discussed.  Based on this synthesis of the 
evidence, a prehospital cTnI testing protocol will be designed and a plan for 
implementation, evaluation, and sustainability outlined in the following chapters. 
  
 
 
 
 
 
Chapter 3 
Project Design and Methodology 
 This chapter discusses the implementation of the Prehospital Testing Protocol as 
guided by the ACE Star Model of Knowledge Transformation.  The Star Model is a 
simple, parsimonious depiction of the relationships between various stages of knowledge 
transformation and places nursing’s previous scientific work within the context of EBP, 
serves as an organizer for examining and applying EBP, and mainstreams nursing into the 
formal network of EBP (Stevens, 2012).  This model was adapted and operationalized for 
the purposes of this implementation project.  Star Point 1 and 2 were covered in Chapter 
1 and 2 and Star Points 3–5 will be covered in this chapter.  See Figure 2 on the following 
page. 
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Figure 2. ACE Star Model of the Cycle Knowledge Transformation. Adapted from “ACE 
Star Model of EBP: Knowledge transformation,” by K. R. Stevens, 2004, Academic 
Center for Evidence-based Practice, 2004 The University of Texas Health Science Center 
at San Antonio 
Project Design and Methodology Overview 
 The project protocol will be applied to all patients encountered in the prehospital 
setting with chest pain, suggestive of an NSTE-ACS.  Each patient will have a serum 
troponin level obtained and tested utilizing a POC platform according to the evidence 
discussed in Chapter One.  T1 will be obtained by prehospital personnel expeditiously 
after FMC along with standard interventional therapies of the EMS system utilized in the 
protocol implementation.  The results of this initial POC test will be provided to the 
receiving ED and incorporated into the patients ongoing treatment plan in an accelerated 
diagnostic protocol.  This accelerated diagnostic protocol will include a T2 value 
obtained 90 minutes to two hours after T1 and a final disposition made based on the 
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comparison of the T1 and T2 values.  Disposition includes: discharge from the ED, 
admission to the hospital, admission to interventional services, or transfer to higher level 
of care, if necessary services are not available at the receiving facility.  
 The population of interest for this project are patients above 18 years, who call 
EMS with complaints of chest pain of potential NSTE-ACS origin.  Non-cardiac sources 
of chest pain include post traumatic chest pain, respiratory chest pain, chest pain of 
infective origin, and chest pain of gastrointestinal origin.  This will include patients of all 
genders, races, and cultural backgrounds. 
Fully Operationalized Project 
 The following diagram in Figure 3 (pages 26 & 27) represents an overview of the 
PHTTP Implementation Plan based on the Prehospital Troponin Logic Model (Appendix 
H).  The specific details of the plan will be outlined following the figure. 
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Figure 3. Prehospital Troponin Testing Protocol 
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Figure 4. Prehospital Troponin Testing Protocol (Continued) 
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Detailed Implementation Plan 
Ethical considerations. 
o Ethics of the conducted research —all the studies incorporated in the body 
of evidence on which the implementation plan is based on met the 
requirements of the ethical research: 
• Scientific value—provided scientific benefit 
• Scientific validity—followed methodological rigor 
• Fair subject selection—ensured appropriate randomization 
• Favorable risk-benefit ratio—evaluates outcomes worth risks 
• Independent review—ensures no conflicts of interest 
• Respect for potential and enrolled subjects—adherence to the 
Declaration of Helinski 
• Informed consent—allowing voluntary informed consent to 
participate 
Ethics of translating the body of evidence into practice. 
o Only the studies that were deemed ethically sound were included in the 
body of evidence 
o The evidence was translated directly into the practice protocol without 
modification 
o The following questions were addressed in the evidence translation 
process to ensure ethical decisions were made: 
• What is the question you want to answer? 
• What are your existing thoughts and feelings about that topic? 
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• How might these thoughts affect your choices about evidence? 
• What can you do to make those choices open and defensible? 
Ethics of project planning. 
o Patient confidentiality and safety are of utmost importance 
o All planning was done with the best interest of the patient in mind and the 
ways in which the project will improve patient outcomes 
o Financial benefit is considered, but it is not the highest end goal of 
implementing this project. 
o Protection of the interests of all stakeholders. 
Ethics of implementation of evidence (or not) and use of patient data. 
o No evidence was included in the implementation plan that was previously 
not deemed ethical. 
o The integrity of protected health information was maintained. 
o All steps in the implementation process are based on ethical decision-
making and the concepts of beneficence and non-beneficence. 
Ethics of dissemination of the evidence (or not). 
o Evidence will be presented objectively with no alterations to potentially 
skew the results into a more favorable direction. 
o Personal opinions will be withheld from the dissemination of evidence. 
o Patient information will be protected. 
Ethics of sustainability. 
o Does the project fulfill its initial goals? 
o What benefits or harms are brought about by sustaining the project? 
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o Does the project support the system or context which makes it possible 
and meaningful? 
o Does the project have the potential to consume all resources prior to 
deriving benefit? 
Ethics of DNP role delivery. 
o Always advocate for the best interests of the patient, their colleagues and 
the system as a whole 
o Strengthen practice environments by improving practice processes based 
on the best evidence 
o Strike a balance between personal and professional values in the 
implementation of practices 
o Ensure that all human rights are protected and that the concept of justice is 
always foremost 
o Employ strategies to maintain the highest ethical standards 
Select project implementation setting. 
o Geographical setting with both rural and urban EMS systems and a 
regional medical center with interventional cardiology services or transfer 
access to a tertiary center or an EMS system that services both rural and 
urban population 
▪ An urban EMS is a system that operates within the confines of a 
city or town with a more concentrated population per square mile 
▪ A rural EMS is a system operates outside of the confines of a city 
or town with a less concentrated population per square mile. 
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▪ The purpose of utilizing both an urban and a rural EMS system is 
based on the average difference in transport times 
o A tertiary center with interventional cardiology services is one that has a 
continuously available cardiac catherization suite with an interventional 
cardiologist continuously on call. 
Process indicators/Outcomes measures. 
o Reduction in time from FMC to T1 
o Reduction in facility LOS 
o No significant increase in EMS scene times 
Anticipated barriers. 
o Collaboration between EMS and ED staff and medical directors – This 
barrier was addressed through collaborative training and round table 
meetings. 
o ED physicians, CV Physicians, and Hospitalists unwilling to use a 
prehospital troponin value – data on the reliability of prehospital troponin 
testing was provided to all ED physician and APP staff 
o Administration of either EMS system unwilling to participate in protocol 
due to initial equipment costs and training expenses – there was no cost to 
the EMS system as all cost was assumed by the project manager. 
o Emergency Department unwilling to participate in project – after an 
extensive search a willing ED Medical Director and ED manager were 
found and provided extensive literature from the EPIP body of evidence. 
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Stakeholder Recruitment and Buy-in. 
 
Figure 5. Prehospital Troponin Project Stakeholder Interaction 
 
o Organizational Recruitment, Buy-in, and Approval to participate 
o Texas Department of State Health Services EMS & Trauma Bureau 
o Plainview Fire-EMS 
o Covenant Plainview Hospital Administration 
EMS & Hospital 
Administration
ED Medical 
Director/EMS 
Medical Director
EMS Staff/ED 
Staff
Chest Pain Patients 
& Family
Cardiology  
Services
Hospitalist 
Services
Laboratory 
Services
Project Manager
Texas DSHS
Medicare/Medicaid 
& Private 
Insurance
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Establishment organizational structure. 
o Lead by Project Implementation Manager (DNP-trained Nurse Scholar) 
o Includes all components from both EMS systems and receiving hospital 
systems 
▪ Administrators 
▪ Medical Directors 
▪ Units 
▪ Personnel 
 
Figure 6. Prehospital Troponin Project Organizational Chart 
 
Project Manager
Hospital 
Administration
ED Medical 
Director
ED Director
ED Staff
Cath Lab 
Director
CATH Lab
Hoapitalist 
Director
Hospitalist
Lab Director
Lab Staff
EMS 
Administration
EMS Medical 
Director
EMS Director
EMS Staff
TX DSHS
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Establishment of committee structure. 
o Protocol Design Committee (PDC) creates a consensus protocol to utilize 
in the implementation of prehospital troponin testing 
o Finance & Purchasing Committee (FPC) explores options for the most 
cost effective attainment of the selected POC assay platform either 
through grant, direct purchase, or rental and then make necessary 
arrangements to acquire the platform 
o Training Committee (TC) develops training protocols, training materials, 
select sites for training sessions, creating a training calendar, and table top 
and simulation trials on the selected and acquired POC platform 
o Implementation and Review Committee determines baseline data, selects 
exact implementation criteria, oversees implementation, and engages in 
process marker monitoring, data review, and protocol adjustment as 
needed based on the process markers. 
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Figure 7. Prehospital Troponin Project Committee Structural Organization 
 
o PDC finalizes proposed protocol call design based on assumptions from 
synthesis of evidence discussed in Chapter 2: 
o Troponin I is the biomarker of choice in the diagnosis of NSTE-ACS 
o Accelerated diagnostic pathways, utilizing high-sensitivity troponin 
testing can reduce the time to diagnosis of NSTE-ACS 
o The use of prehospital troponin testing in combination with an accelerated 
diagnostic protocol can further reduce diagnostic time by as much as 0.29 
hours in the urban setting according Ezekowitz (2015) and potentially 
higher in the rural setting 
o POC troponin testing in moving ambulances is not statistically different 
from POC troponin  
• Project Manager
• Administratiom
• Medical Directors
• Department Directors
• Selected Staff
• Project Manager
• ED, EMS Directors, 
Lab Directors
• EMS Field Training 
Officers
• Project Manager
• EMS Administration
• ED & EMS Directors
• Project Manager
• Medical Directors
• Unit Directors
Protocol Design 
Committee
Finance & 
Purchasing 
Committee
Implemmentation 
& Review 
Committee
Training 
Committee
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Establishment of protocol and training structure 
 
Figure 8. Prehospital Troponin Testing Protocol 
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o FPC meets, evaluates, selects, and obtains a POC cTnI assay platform 
o TC meets and finalizes training protocol based on equipment obtained 
 
 
Figure 9 Prehospital Troponin Testing POC Training protocol 
Training of EMS personnel. 
o EMS Medical Director 
o EMS Supervisors 
o EMS Field Training Officer 
o EMS Field Personnel 
o Protocol Compliance Officer 
ED Equipment 
Demonstration
Power     point 
Presentation
Equipment 
demonstration 
w/proper serum 
sampling
Written Testing
Psychomotor Skils 
Testing
CME Granted
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o Exact training details will be determined by the exact POC testing 
platform selected and serum sampling will be based on existing EMS 
protocols. 
Dissemination of project implementation progress to stakeholders. 
o Final Approved Protocol 
o POC Testing Platform 
o Training Plans 
o Request for feedback 
PDC & TC review feedback from stakeholders. 
o Testing Protocol 
o POC Testing Platform 
o Training Protocol 
o Appropriate adjustments made 
Tabletop simulations of POC platform with EMS personnel. 
o TC members perform 10 tests on POC platform with same samples tested 
by receiving ED for validation 
Field simulations performed in ambulances. 
o TC members perform 10 tests on POC platform in moving ambulance 
simulation with same samples tested by receiving ED for validation 
Dissemination of simulation results to stakeholders from simulations. 
o Review Prehospital Troponin Testing Protocol 
o Review training records 
o Review simulation results 
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o Implementation plan developed 
o Implementation date determined 
Table 1. Prehospital Troponin Testing Protocol 
PREHOSPITAL TROPONIN 
TESTING PROTOCOL (PTTP) 
EVIDENCE 
STEP 1: Eligible Patient Selected 
(Patient Population) who is > 18 years of 
age with chest pain of suspected cardiac 
origin with onset of symptoms < 12 
hours. 
 
Amsterdam (2014) – Guidelines of 
ACC/AHA for Management for NSTE-
ACS: 
o Risk for NSTE-ACS  > 18 y/o 
o Other causes of non-NSTE-ACS 
chest pain: trauma, neurological, 
respiratory, gastrointestinal, 
genitourinary 
o Symptoms > 12 hours from onset 
make troponin assays unreliable 
Roffi (2015) - chest discomfort is leading 
symptom that initiates the 
diagnostic and therapeutic cascade 
in patients with suspected ACS and 
chest discomfort patients 
frequently utilize emergency 
medical services (EMS) for 
transport to the ED 
STEP 2: Initial 12 Lead EKG Obtained 
and send to receiving ED. If ST segment 
elevation is present STOP PTTP and 
proceed with STE-ACS Management 
Amsterdam (2014) – Guidelines of 
ACC/AHA for Management for NSTE-
ACS: 
o Obtained as soon as possible after 
onset of symptoms 
o ST elevation indicates STE-ACS – 
alert ED & PCI Services. 
Medications according to Level II 
guidelines. 
STEP 3: First troponin obtained via POC 
cTnI troponin testing platform. If 
troponin is + NSTE-ACS Diagnosis – 
alert ED for EIS initiation 
Amsterdam (2014) – Guidelines of 
ACC/AHA for Management of NSTE-
ACS: 
o Obtain first troponin as soon as 
possible after onset of symptoms 
Appendix D – Study Methodology 
Synthesis Table 
Borna (2016) they demonstrated that cTnI 
testing was a superior biomarker to 
diagnose NSTE-ACS 
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Ezokowitz (2015) use of prehospital 
troponin testing reduces the time to 
diagnosis and intervention 
Morrow (2001) demonstrated patients with 
clinically documented NSTE-ACS 
derive a large clinical benefit from 
the utilization of an EIS 
Sorenson (2011) indicated implementation 
of quantitative prehospital troponin 
testing by paramedics is feasible 
and effective 
Venturini, 2013 - utilization of prehospital 
personnel to use POC devices to 
measure cTnI levels during 
transport of patients to the ED may 
result in earlier diagnosis of NSTE-
ACS  
STEP 4: Patient transport to receiving 
ED and second troponin is obtained in 90 
minutes to 2 hours 
Amsterdam (2014) – Guidelines of 
ACC/AHA for Management for 
NSTE-ACS - Diagnostic pathway 
for NSTE-ACS should be less than 
2 hours from FMC 
Khera (2014) - consistent benefit in the 
utilization of EIS in the setting of 
NSTE-ACS especially in the 
setting of high-risk populations 
Layfield (2014) - serial cTnI sampling 
with one sample at presentation 
and at least one additional sample 
collected two hours later was 
necessary to identify a rise or fall 
in the troponin level 
Wallentin (2016) - early EIS postponed 
the occurrence of death or next 
acute coronary event by an average 
of eighteen months, and 
readmission to the hospital for 
ischemic heart disease by thirty-
seven months, compared with a 
non-invasive strategy in patients 
with NSTE-ACS  
 
Feedback results from stakeholders reviewed.  
o Necessary revisions made based on feedback 
Table 1. Prehospital Troponin Testing Protocol 
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Data collection. 
o Time of First Medical Contact (FMC) 
o Time of First Troponin (T1) 
o Time of second troponin (T2) 
o Time of Disposition 
o FMC to T1 
o FMC to Disposition (LOS) 
Baseline ED and EMS data to be obtained. 
o ED Electronic Medical Records (EMR) 
o EMS EMR/Written records and Computer-aided Dispatch (CAD) records 
 
Table 2. Project Implementation Timeline with Process Markers 
WHEN:  
January 15, 2019 WHAT: Secure buy-in and willingness to 
participate in project implementation 
from key stakeholders. Refer to 
stakeholder diagram for key stakeholders.  
WHO: Project Implementation Manager 
WHERE: Plainview, Texas 
HOW: Presentation of EPIP slideshow 
and distribution of key point pamphlets. 
Obtain appropriate contact information 
and schedule subsequent meetings either 
in person, via Zoom or WebEx, or email.  
January 21, 2019 WHAT: Revisit stakeholders and obtain 
necessary agreements to participate.  
WHO: Project Implementation Manager 
from Texas DSHS, EMS administration, 
and ED administration. These include the 
EMS Medical Director, Fire Chief, ED 
Medical Director and ED Director. Select 
committee members for each of the four 
committees. 
WHERE: Plainview, Texas 
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HOW: In person, via Zoom, WebEx, or 
email 
January 28, 2019 WHAT: Finalization of protocol design 
WHO: Project protocol design committee 
and PIM. 
WHERE: Plainview, Texas 
HOW: In person, via Zoom, WebEx, or 
email 
February 1, 2019 WHAT: Disseminate results from both 
Protocol Design Committee and Finance 
Committee to all stakeholders and elicit 
feedback. Compile feedback for next 
round of committee meetings. 
WHO: PIM 
WHERE: Plainview, Texas 
HOW: In person, via Zoom, WebEx, or 
email 
February 5, 2019 WHAT: Finalizes protocol with 
consideration of equipment selected by 
Finance Committee and distributes final 
protocol to direct stakeholders and 
requests feedback. 
WHO: Protocol Design Committee and 
PIM 
WHERE: Plainview, Texas 
HOW: In person, via Zoom, WebEx, or 
email 
February 12, 2019 WHAT: Make final decision regarding 
equipment, financial acquisition plan is 
made based on financial resources 
selected (grant, rent, or purchase). The i-
STAT POC platform offers a rental 
option in addition to a purchase option. 
WHO: Finance Committee & PIM 
WHERE: Plainview, Texas 
HOW: In person, via Zoom, WebEx, or 
email 
February 15, 2019 WHAT: Design training program in 
coordination with manufacturer 
guidelines. Training materials are created 
and finalized. The training program will 
include serum sample acquisition, POC 
platform usage, POC cartridge handling 
and storage, and serum sample handling.  
WHO: Training Committee and PIM 
WHERE: Plainview, Texas 
Table 2. Project Implementation Timeline with Process Markers (Continued) 
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HOW: In person, via Zoom, WebEx, or 
email 
February 21, 2019 WHAT; Equipment orientation and 
training begins with EMS staff and 
demonstration to ED staff.  This training 
will include testing on actual POC 
platform and will include skills testing 
and CEU hours for EMS staff. 
WHO: PIM, Training Committee, EMS 
Training Officers. PIM coordinates with 
EMS Director and EMS training staff and 
ED Director. 
WHERE: At preselected and secured 
sites in the local area. 
HOW: In person with psychomotor skills 
lab. Recorded for internet distribution to 
staff that could not attend. 
February 22, 2019 WHAT: Equipment training is completed 
and table top testing initiated. Table top 
testing is testing with POC platform 
quantitative testing solutions in simulated 
EMS scenarios. Table top results will be 
disseminated to stakeholders and 
feedback requested.  
WHO: PIM, Training Committee, 
Implementation & Review Committee, 
EMS Medical Director, and EMS 
Training Staff. 
WHERE: Plainview, Texas 
HOW: In person in the local area. 
February 23, 2019 WHAT: Mach patient testing in EMS 
vehicle patient simulations with 
comparison to ED values on same serum 
samples. Serum samples will be testing in 
a moving ambulance and the same sample 
will then be testing in the ED setting to 
validate the accuracy of prehospital 
troponin testing. These results will be 
disseminated to all stakeholders and 
feedback requested. 
WHO: PIM, Training Committee, EMS 
Training Staff, Equipment Committee, 
Medical Directors, Laboratory staff, ED 
& EMS Directors. 
WHERE: Ambulances from the local 
EMS selected for the project 
Table 2. Project Implementation Timeline with Process Markers (Continued) 
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implementation. Receiving ED utilized 
for project. 
HOW: In person 
February 25, 2019 WHAT: Protocol reviewed and finalized 
for implementation. Revisit with direct 
and indirect stakeholders and provide 
status reports and request feedback. All 
testing results and feedback review and 
any suggested changes implemented and 
final protocol disseminated to 
stakeholders and final approval obtained. 
WHO: PIM, Protocol Design Committee, 
Training Committee, Implementation & 
Review Committee, Interested 
stakeholders, Medical Directors, 
Administrators and Industry Mentor. 
WHERE: Plainview, Texas 
HOW: In person, via Zoom, WebEx, or 
email 
February 28, 2019 WHAT: Full scale protocol initiation.  
WHO: An expert group consisting of 
PIM, Implementation & Review 
Committee, Training Committee, EMS 
Medical Director, ED Medical Director, 
Project Manager, EMS Director and ED 
Director. 
WHERE: EMS ambulances and ED. 
HOW: In person 
March 5, 2019 WHAT: Process markers evaluated. First 
data set compiled and reviewed. 
Stakeholders notified of results and 
feedback requested. Review the process 
markers and make adjustments as 
necessary. 
WHO: PIM and all interested parties. 
WHERE: Plainview, Texas 
HOW: In person, via Zoom, WebEx, or 
email 
March 10, 2019 WHAT: Second data set compiled and 
evaluated. Data charts updated and 
variances identified and protocol 
adjustments made if needed. 
WHO: PIM, Implementation & Review 
Committee, Industry Mentor, Medical 
Directors, Administrators, and interested 
stakeholders 
Table 2. Project Implementation Timeline with Process Markers (Continued) 
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WHERE: Plainview, Texas 
HOW: In person, via Zoom, WebEx, or 
email 
March 17, 2019 WHAT: Third data set compiled and 
evaluated. Data charts updated and 
variances identified and protocol 
adjustments made if needed. 
WHO: PIM, Implementation & Review 
Committee, Industry Mentor, Medical 
Directors, Administrators, and interested 
stakeholders 
WHERE: Plainview, Texas 
HOW: In person, via Zoom, WebEx, or 
email 
March 26, 2019 WHAT: Initial implementation complete 
WHO: PIM, Implementation & Review 
Committee, Industry Mentor, Medical 
Directors, Administrators, and interested 
stakeholders 
WHERE: Plainview, Texas 
HOW: In person, via Zoom, WebEx, or 
email 
 
Table 2. Project Implementation Timeline with Process Markers (Continued) 
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Figure 10. Final Prehospital Troponin Testing Protocol Project resources. 
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o EMS service with ambulances and at least one Texas Department of State 
Health Services certified/licensed paramedic or Nationally Registered 
Emergency Medical Technician – Paramedic 
o IV start equipment 
o Blood sampling equipment 
o POC Troponin Test Platform with storage system 
o Appropriate Troponin I Cartridges 
o Printer Paper for POC Platform 
o Green Top Serum Blood Tubes 
o Serum Blood Sampling Pipets 
o Training Materials (Pamphlets) 
o Training Sites 
o Serum Blood Samples or manufacturer testing solutions 
o EMS Vehicles for simulation testing 
o Computer or tablet for data set storage, email, and presentation 
o Computer Aided Dispatch System capable of documenting EMS response 
variables 
o EMR capable of accurately documenting patient care and times 
o Printer  
o Office Supplies (Paper, Ink, Legal Pads, Pens, etc. 
Financial analysis for 30-day implementation. 
i-STAT Analyzer Rental/month ($599X2) = $1,198 
i-STAT Printer Rental/month ($125X2) = $250 
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i-STAT cTnI Cartridges/25 ($629.95X2) = $1,259.90 
i-STAT Rental Deposit ($7500X2) = $15,000 
3 mL Plastic Pipet (200) = $8.99 
BD Vacutainer Blue Citrate 2.7 mL Tubes (100) = $16.74 
DB Vacutainer (100) = $33.95 
Biohazard Bags (100) = $12.65 
           TOTAL = $17,780.23 
                   - $15,000.00 
           NET     = $ 2,780.23 
Evaluation of Models in PHTTP 
 The ACE Star Model for Knowledge Transformation and Lippitt’s Change theory 
were both effective in ensuring success for this implementation.  The steps of the change 
theory were congruent with this type of implementation and the Star Model was 
beneficial as a tool to justify changes in the current ways of thinking regarding troponin 
testing, utilization of EMS in this change, and the knowledge shift necessary to create this 
shift.  The Star Model was particularly useful in that it organized both old and new 
concepts to improve care into a collective unit and provided a framework to organize the 
process.  The PHTTP was a combination of older concepts (two troponin values must be 
performed in the ED) and a newer concept (performing one troponin outside the ED) into 
its current form (one troponin in the prehospital environment and one in the ED). 
 Conclusion 
  The PHTTP has the potential to save significant annual health care expenses with 
only a limited initial investment and limited continuing expenses in relation to potential 
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benefits.  These benefits can be realized through the reduction in time from FMC to T1, 
reduction in LOS, and reduction in time to EIS.  This protocol will also reduce the impact 
of MACE events in NSTE-ACS patients over its widespread implementation.  These 
benefits will improve patient outcomes and reduce the economic impact of patients with 
NSTE-ACS diagnosis.  American EDs are currently in crisis as they have become the 
health care safety net, which has led to dangerous overcrowding.  Projects such as this 
one that aim not only at improving patient care but also at reducing ED overcrowding 
through improvement in ED workflow could be pivotal in managing the ED crisis.  
  
 
 
 
 
 
Chapter 4 
Project Outcomes, Impact, and Results 
Completion Outcomes 
 The completion outcomes to be measured by the PHTTP include: 
• Reduction in mean time from FMC to T1 
• Reduction in mean LOS 
• No significant change in mean EMS scene times 
Data Collection, Measurement, and Analysis 
 All implementation data points were recording in minute format (XX.XX 
minutes).  EMS times were obtained from written run reports, POC equipment and 
computer-aided dispatch (CAD) equipment used by the Plainview Fire-EMS Department 
for 30 days preceding implementation of the PHTTP.  ED times were acquired from the 
Covenant Plainview ED Meditech EMR for 30 days preceding implementation of the 
PHTTP.  Change in FMC to T1 = (mean pre-implementation FMC to T1 - mean post 
implementation FMC to T1).  Change in LOS = (mean pre-implementation LOS - mean 
post implementation LOS).   Change in EMS scene time = mean pre-implementation 
scene time - pre-implementation scene times).  Times were converted to fractional hours 
by divided by 60 minutes.  Percent change = (post implementation value/pre-
implementation value) X 100.  Statistical significance was calculated using a Single 
Sample t-Test with a two-tailed hypothesis and a 0.05 significance level. 
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Pre-implementation data. 
 The mean ED LOS for 30 days preceding the project implementation was 191-
minutes (3.18 hours) and mean FMC to T1 was 79-minutes (1.32 hours).  Mean EMS 
scene time for 30 days preceding implementation was 13 minutes (0.22 hours). 
Project results and impact. 
 Table 3. Prehospital Troponin Testing Protocol - Field Data 
 
LEGEND: 
AD Admission   FMC First Medical Contact 
ARRIVE ED Arrival at ED ID Unique Patient Identifier 
DC Discharge   LOS Length of Stay 
DEPART ED Depart to ED M Male   
DISPO Disposition    T1 First Troponin Value 
F Female   T2 Second Troponin Value 
 
ID AGE SEX FMC DEPART 
ED 
T1 RESULT ARRIVE 
ED 
001 48 M 10:04 10:18 10:28 NEG 10:30 
002 39 M 4:44 4:55 5:07 NEG 5:07 
003 70 F 15:22 15:37 15:45 NEG 15:47 
004 44 F 8:22 8:35 8:46 NEG 8:48 
005 69 M 22:53 23:08 23:10 POS NA 
006 52 F 6:14 6:24 6:30 NEG 6:31 
007 61 M 10:19 10:35 10:44 NEG 10:44 
008 29 F 5:21 5:41 5:46 NEG 5:48 
009 39 M 16:27 16:39 16:47 NEG 16:50 
010 60 M 18:10 18:28 18:35 NEG 18:52 
011 57 M 7:01 7:16 7:23 NEG 8:04 
012 66 F 5:10 5:28 5:22 NEG 5:37 
013 40 F 11:14 11:33 11:32 NEG 11:33 
014 66 M 8:01 8:20 8:23 NEG 8:21 
015 79 M 5:32 5:44 6:01 NEG 6:09 
016 47 M 12:12 12:28 12:35 NEG 12:31 
017 66 M 19:08 19:35 19:32 NEG 19:36 
018 81 F 6:15 6:31 6:41 NEG 6:36 
019 59 F 11:15 11:33 11:39 NEG 11:39 
020 54 F 21:14 21:30 21:40 NEG 21:48 
021 90 M 4:22 4:37 4:39 NEG 4:50 
022 51 F 12:01 12:16 12:18 NEG 12:20 
023 30 M 16:23 16:35 16:47 NEG 16:50 
024 49 M 8:10 8:21 8:35 NEG 8:33 
025 60 F 14:17 14:29 14:40 NEG 14:44 
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Table 4. Prehospital Troponin Testing Protocol - ED Data 
LEGEND: 
AD Admission   FMC First Medical Contact 
ARRIVE ED Arrival at ED ID Unique Patient Identifier 
DC Discharge   LOS Length of Stay 
DEPART ED Depart to ED M Male   
DISPO Disposition    T1 First Troponin Value 
F Female   T2 Second Troponin Value 
 
 
 
 
T2 RESULT DISPO LOS DIFF 
11:55 NEG 13:01 DC 151.00 40.00 
6:32 NEG 7:48 DC 161.00 30.00 
17:17 NEG 17:51 AD 124.00 67.00 
10:00 NEG 11:01 DC 133.00 58.00 
NA NA NA NA NA NA 
7:40 NEG 8:44 DC 133.00 58.00 
12:01 NEG 13:19 AD 155.00 36.00 
6:05 NEG 8:33 DC 165.00 26.00 
18:09 NEG 19:10 DC 140.00 51.00 
18:43 NEG 21:21 AD 149.00 42.00 
8:45 NEG 10:34 DC 150.00 41.00 
6:59 NEG 8:52 DC 195.00 -4.00 
12:59 NEG 14:12 DC 159.00 32.00 
10:02 NEG 10:47 DC 146.00 45.00 
8:00 NEG 9:12 T 183.00 8.00 
14:07 NEG 14:25 DC 114.00 77.00 
21:17 NEG 22:01 AD 145.00 46.00 
8:30 NEG 9:05 AD 149.00 42.00 
13:28 NEG 14:20 DC 161.00 30.00 
23:25 NEG 23:52 DC 124.00 67.00 
6:35 NEG 7:10 AD 140.00 51.00 
14:17 NEG 14:54 DC 154.00 37.00 
18:30 NEG 19:12 DC 142.00 49.00 
10:24 NEG 11:33 DC 180.00 11.00 
        16:20 NEG 17:12 DC 148.00 43.00 
LOS   150.04   AVERAGE LOS CHANGE 40.96 
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Table 5. Prehospital Troponin Testing Project Age Distribution 
ID AGE 
001 48 
002 39 
003 70 
004 44 
005 69 
006 52 
007 61 
008 29 
009 39 
010 60 
011 57 
012 66 
013 40 
014 66 
015 79 
016 47 
017 66 
018 81 
019 59 
020 54 
021 90 
022 51 
023 30 
024 49 
025 60 
AVERAGE 56.24 
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Table 6. Prehospital Troponin Testing Project Gender Distribution 
MALE 14 56% 
FEMALE 11 44% 
 
Table 7. Prehospital Troponin Testing Project FMC to First Troponin Average 
ID FMC T1 DIFF 
001 10:04 10:28 0:24 
002 4:44 5:07 0:23 
003 15:22 15:45 0:23 
004 8:22 8:46 0:24 
005 22:53 23:10 0:17 
006 6:14 6:30 0:16 
007 10:19 10:44 0:25 
008 5:21 5:46 0:25 
009 16:27 16:47 0:20 
010 18:10 18:35 0:25 
011 7:01 7:23 0:22 
012 5:10 5:22 0:12 
013 11:14 11:32 0:18 
014 8:01 8:23 0:22 
015 5:32 6:01 0:29 
016 12:12 12:35 0:23 
017 19:08 19:32 0:24 
018 6:15 6:41 0:26 
019 11:15 11:39 0:24 
020 21:14 21:40 0:26 
021 4:22 4:39 0:17 
022 12:01 12:18 0:17 
023 16:23 16:47 0:24 
024 8:10 8:35 0:25 
025 14:17 14:40 0:23 
  
AVERAGE 0:22 
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Table 8. Prehospital Troponin Testing Project FMC to Arrival at Emergency Department 
ID FMC ARRIVE ED DIFF 
001 10:04 10:30 0:26 
002 4:44 5:07 0:23 
003 15:22 15:47 0:25 
004 8:22 8:48 0:26 
005 22:53 NA NA 
006 6:14 6:31 0:17 
007 10:19 10:44 0:25 
008 5:21 5:48 0:27 
009 16:27 16:50 0:23 
010 18:10 18:52 0:42 
011 7:01 8:04 1:03 
012 5:10 5:37 0:27 
013 11:14 11:33 0:19 
014 8:01 8:21 0:20 
015 5:32 6:09 0:37 
016 12:12 12:31 0:19 
017 19:08 19:36 0:28 
018 6:15 6:36 0:21 
019 11:15 11:39 0:24 
020 21:14 21:48 0:34 
021 4:22 4:50 0:28 
022 12:01 12:20 0:19 
023 16:23 16:50 0:27 
024 8:10 8:33 0:23 
025 14:17 14:44 0:27 
  
AVERAGE 0:27 
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Table 9. Prehospital Troponin Testing Project Troponin 1 to Troponin 2 Average 
ID T1 T2 DIFF 
001 10:28 11:55 1:27 
002 5:07 6:32 1:25 
003 15:45 17:17 1:32 
004 8:46 10:00 1:14 
005 23:10 NA NA 
006 6:30 7:40 1:10 
007 10:44 12:01 1:17 
008 5:46 6:05 0:19 
009 16:47 18:09 1:22 
010 18:35 18:43 0:08 
011 7:23 8:45 1:22 
012 5:22 6:59 1:37 
013 11:32 12:59 1:27 
014 8:23 10:02 1:39 
015 6:01 8:00 1:59 
016 12:35 14:07 1:32 
017 19:32 21:17 1:45 
018 6:41 8:30 1:49 
019 11:39 13:28 1:49 
020 21:40 23:18 1:38 
021 4:39 6:35 1:56 
022 12:18 14:17 1:59 
023 16:47 18:30 1:43 
024 8:35 10:24 1:49 
025 14:40 16:20 1:40 
  
AVERAGE 1:29 
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Table 10. Prehospital Troponin Testing Project Troponin 2 to Disposition Average 
ID T2 DISPO DIFF 
001 11:55 13:01 1:06 
002 6:32 7:48 1:16 
003 17:17 17:51 0:34 
004 10:00 11:01 1:01 
005 NA NA NA 
006 7:40 8:44 1:04 
007 12:01 13:19 1:18 
008 6:05 8:33 2:28 
009 18:09 19:10 1:01 
010 18:43 21:21 2:38 
011 8:45 10:34 1:49 
012 6:59 8:52 1:53 
013 12:59 14:12 1:13 
014 10:02 10:47 0:45 
015 8:00 9:12 1:12 
016 14:07 14:25 0:18 
017 21:17 22:01 0:44 
018 8:30 9:05 0:35 
019 13:28 14:20 0:52 
020 23:25 23:52 0:27 
021 6:35 7:10 0:35 
022 14:17 14:54 0:37 
023 18:30 19:12 0:42 
024 10:24 11:33 1:09 
025 16:20 17:12 0:52 
  
AVERAGE 1:05 
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Table 11. Prehospital Troponin Testing Project EMS Scene Time 
ID FMC DEPART DIFF 
001 10:04 10:18 0:14 
002 4:44 4:55 0:11 
003 15:22 15:37 0:15 
004 8:22 8:35 0:13 
005 22:53 23:08 0:15 
006 6:14 6:24 0:10 
007 NA 10:35 NA 
008 5:21 5:41 0:20 
009 16:27 16:39 0:12 
010 18:10 18:28 0:18 
011 7:01 7:16 0:15 
012 5:10 5:28 0:18 
013 11:14 11:33 0:19 
014 8:01 8:20 0:19 
015 5:32 5:44 0:12 
016 12:12 12:28 0:16 
017 19:08 19:35 0:27 
018 6:15 6:31 0:16 
019 11:15 11:33 0:18 
020 21:14 21:30 0:16 
021 4:22 4:37 0:15 
022 12:01 12:16 0:15 
023 16:23 16:35 0:12 
024 8:10 8:21 0:11 
025 14:17 14:29 0:12 
  
AVERAGE 0:15 
  
  81 
 There were 25 eligible patients included in the 30 day preliminary PHTTP data 
set.  One patient was excluded for a positive T1 and ST segment elevation on ECG and a 
subsequent diagnosis of STEMI.  The average ago of the study participants was 56.24 
years and 56% male and 44% female.  The PHTTP preliminary data demonstrated a 
reduction in the time of mean FMC to T1 from 79 minutes (1.32 hours) to 22 minutes 
(0.37 hours) and mean FMC to disposition of patients from 191.00 minutes (3.18 hour) to 
150.04 minutes (2.50 hours).  Mean FMC to T1 was reduced by 47.00 minutes (0.78 
hours) and LOS was reduced by 40.96 minutes (0.67 hours).  This equated to a 21.19% 
reduction in mean ED LOS of this subset of patients in the Covenant Plainview ED.  The 
mean EMS scene time increased from 14 minutes (0.23 hours) to 15 minutes (0.25 
hours).  During the implementation period the mean time to return of T1 was reduced to 
10 minutes (0.17 hours) through POC testing which equated to a reduction of 57 minutes 
(0.95 hours) or a 14.9% improvement.  Mean return time of T2 was not significantly 
different at 78 minutes (1.32 hours), compared to 79 minutes (1.32 hours) as it was 
processed in the Covenant Plainview Lab with via the same instrumentation and protocol.  
The mean LOS was reduced from 191 minutes (3.18 hours) to 150.04-minutes (2.5 hours) 
which equated to a reduction of 40.96-minutes (0.67 hours) or a 21.19% improvement.  
Analysis. 
 The sample data was analyzed using a Single Sample t-Test with a two-tailed 
hypothesis and a 0.05 significance level.  This test was used to determine if the post 
implementation values were statistically different from the pre-implementation values.  
The time from mean FMC to T1 t-value = -10.665324 at p = < 0.00001 and LOS t-value 
= -72.249049 at p = < 0.00001 which are both statistically significant at p = 0.05.  Mean 
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EMS scene time t-value = 1.790249 at p = 0.086588 which is not statistically significant 
at p = 0.05.   
Conclusion 
 The preliminary results of the PHTTP corresponded with the postulated outcome 
measures by reducing the mean time to final disposition and mean LOS of chest pain 
patients that arrived at the ED via EMS.  These measures were attained through the 
introduction of a prehospital troponin value that reduced the time from mean FMC to T1.  
The reduction in time from mean FMC to T1 concomitantly reduced the mean LOS 
without a significant increase in mean EMS scene time of chest pain patients transported 
by Plainview Fire-EMS to Covenant Plainview ED. 
 
  
 
 
 
 
 
Chapter 5 
Project Sustainability, Discussion, Conclusions, and Dissemination Recommendations 
Discussion of Results and Impact 
 The PHTTP preliminary data demonstrated a reduction in the time from mean 
FMC to T1 and mean FMC to disposition of patients who were transported to the 
Covenant Plainview ED via Plainview Fire-EMS from 191 minutes (3.18 hour) to 150.04 
minutes (2.50 hours).  This reduced the mean LOS by 40.96 minutes (0.67 hours).  This 
equated to a 21.19% reduction in mean ED LOS for this subset of patients in the 
Covenant Plainview ED.  This reduction in time to T1 had the following immediate 
impacts: 1) reduced the time from mean FMC to T2, 2) reduced the time from mean FMC 
to T2, and 3) reduced the time from mean FMC to final disposition which could include 
discharge, admission, or transfer.  Its intermediate impacts include the following: 1) 
reduction in time to EIS and 2) reduction in ED overcrowding and improved ED 
workflow.  Long-term impacts potentially include the following: 1) improved patient 
outcomes through reduction in 90-day MACE events, 2) improved ED patient 
satisfaction, 3) improved Fire-EMS and ED collaboration and satisfaction, and 4) reduced 
institutional costs from subsequent hospitalization related to 90-day MACE.  The 
potential long-term impacts require ongoing implementation of the PHTTP to validate. 
 Project Sustainability Plans and Implementation 
 Sustainability occurs through standardization and conservation of new practices 
over time requiring stakeholders, including management and staff to fundamentally alter 
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their thinking and attitudes towards a process innovation.  Sustainable change in health 
care must be dynamic and adaptive to meet contextual needs and maintain desirable 
patient outcomes (Scheirer & Dearing, 2011).  Refer to Figure 9 for PHTTP 
sustainability plan.   
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Figure 11. Prehospital Troponin Testing Project Sustainability Plan 
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Dissemination, feedback, and adjustment phases.  
The initial step of ensuring the sustainability of the PHTTP is to maintain the 
engagement and investment of the key stakeholders, as well as identifying additional 
stakeholders and potential barriers to ongoing sustainability.  The dissemination of the 
preliminary results of the PHTTP to stakeholders will be done through a combination of 
media formats including print, electronic, and in-person presentations via presentation 
platforms such as Microsoft PowerPoint.  This media will be distributed to the 
administration of both the Covenant Plainview Hospital, the Plainview Fire-EMS 
Department, and the City of Plainview. An article will be written for publication in the 
Plainview Daily Herald detailing the PHTTP and the involvement of both the fire 
department and the hospital ED.  This process of preliminary result and project 
dissemination will identify any potential stakeholder, financial, political, or organization-
related barriers and aid in developing potential strategies necessary to overcome these 
barriers and facilitate ongoing implementation of the PHTTP. 
Potential barrier and their solutions are as follows:  
• Stakeholder: All major stakeholders involved in the PHTTP were initially vested 
and discussions of their preliminary results demonstrated continued investment.  
The official dissemination of the preliminary data in additional to the concurrent 
data collection will assist in continuing their involvement and participation.   
• Financial: Ongoing expense of sustaining the PHTTP.  There is an initial durable 
and ongoing consumable equipment cost, but it can be offset over the long-term 
as troponin testing is a reimbursable intervention by major insurance providers, 
Medicare, and Medicaid (Kip, 2017).  The Texas Department of State Health 
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Services has many grant services available for licensed EMS providers in the 
State of Texas and the preliminary data from PHTTP will be utilized with grant 
writing (Texas Department of State Health Services, 2019).  In conjunction with 
the Plainview Fire-EMS, grant applications will be made to U.S. and Texas 
Department of State Health Services (DHS) and Department of Homeland 
Security Federal Emergency Management Agency (FEMA) to obtain permanent 
durable POC and consumable equipment to fund the ongoing training and 
education.  Additionally, a billing policy will be implemented to ensure 
appropriate reimbursement to the Plainview Fire-EMS for POC troponin testing to 
sustain ongoing consumable equipment procurement.  These steps will support 
the continuation of the PHTTP until adequate reimbursement has been obtained 
and the PHTTP is self-sustained. 
• Political: There was a concern regarding the increased liability of the City of 
Plainview using the fire department to perform tests previously completed by the 
hospital laboratory.  The city attorney was provided the literature that 
demonstrated no increase in liability from the utilization of POC testing and that 
POC testing is the standard of care in the management of chest pain patients 
(Juliano, 2017). 
• Organizational: Plainview Clinical Laboratory resisted the continuation of 
PHTTP.  The Plainview Clinical Laboratory demonstrated initial resistance to 
troponin values being obtained outside of their facility due to potential lack of 
reliability, loss of revenue, and lack of Clinical Laboratory Improvement 
Amendments (CLIA) certification.  These issues were addressed via in-person 
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meetings and the provision of literature regarding the reliability of out-of-
laboratory troponin results (Juliano, 2017), demonstration of troponin testing 
platform, cost benefit analysis regarding reagents, cartridges, staff, and equipment 
maintenance cost regarding potential billing amounts, and documentation of POC 
troponin testing being a CLIA-waived test (Center’s for Medicare and Medicaid 
Services, 2018).  
Plan for initial dissemination of preliminary data.  
 This plan includes the following: 1) In-person or round table meeting with key 
stakeholders to disseminate the preliminary results of the PHTTP and address any 
potential barriers to continued implementation, 2) presentation to city council and 
publication of preliminary results and involvement of important stakeholders in city 
newspaper and fire department, hospital, and city website, 3) meetings with financial 
officers of City of Plainview and Covenant Plainview Hospital as well as meeting with 
Texas Department of State Health Services EMS Grants Division, 4) community 
presentation to interested individuals, and 5) publication in selected journals. 
Dissemination. 
• Oral presentation with PowerPoint Slides to DNP cohort, UT Tyler DNP 
Faculty, Covenant Plainview ED staff and administration, Plainview Fire-
EMS and Plainview City Council 
• Newspaper articles presentation 
• Poster presentation to stakeholders 
• Community meetings 
• Media announcements: Radio/Television 
  89 
• Presentation at Texas EMS conference 
• Article publications in scholarly journals: 
• Academic Emergency Medicine 
• Journal of Advanced Emergency Nursing 
• Journal of the American College of Cardiology 
• Journal of Prehospital Emergency Care 
• Journal of Emergency Medical Services 
 Funding phase.  
 Sustainability of the PHTTP requires ongoing funding from the host 
organizations.  This funding can be secured from internal as well as external sources. 
Internal sources of funding include inclusion in departmental and organizational 
budgetary planning meetings with the Chief Financial Officers of both host organizations 
and meetings with billing agencies to procure appropriate reimbursement for POC testing 
as outlined by CMS.  External sources of funding include donations from community 
partners identified through dissemination of preliminary results at town hall meetings and 
media, private funding organizations such as Abbott Point-of-Care, and grant applications 
that will be made to the United States and Texas Department of State Health Services 
(DHS), and Department of Homeland Security Federal Emergency Management Agency 
(FEMA). 
 Dynamic re-evaluation phase.  
 As the PHTTP continues within the host organizations a continual evaluation and 
of project outcomes and dynamic adjustment to problems or new barriers is necessary. 
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Sustainability cannot be maintained within a static situation and continual dynamic 
change based on outcomes measures and stakeholder feedback must occur. 
Organizational readiness phase.  
 The readiness of the host organizations for sustained change must be assessed 
prior to full project integration to assess organizational strengths and weaknesses.  The 
Organizational Readiness for Change Assessment (ORCA) tool will be utilized to re-
evaluate the readiness of the host organizations prior to full and sustained implementation 
following the initial implementation phase.  The ORCA tool is utilized to identify and 
monitor the organizational strengths and weaknesses to support a sustain implementation 
of evidence-based practices (Helfrich, 2009).  Any weaknesses identified will be 
addressed with organizational leadership and adaptations made to facilitate complete 
project integration and sustainability. 
 Project integration phase.  
 PHTTP is integrated in the budget, facility protocols, and training practices at 
both host organizations as a Standard Operating Procedure (SOP) through Project 
Integration Management (PIM).  PIM is the process of integrating new processes into a 
complex, fully functional system to minimize system interruption and create sustainable 
system change (Project Management Institute, 2017). 
 The utilization of the PHTTP sustainability plan will create a sustainable change 
within both the Plainview Fire-EMS Department and the Covenant Plainview ED.  This 
sustainable change will improve inter-professional collaboration between these 
organizations, improve outcomes of chest pain patients, improve ED workflow, and 
reduce ED overcrowding. 
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Implications of PHTTP Results 
 The preliminary results of the PHTTP have implications in the ongoing 
management of chest pain patients transported to the Covenant Plainview ED via 
Plainview Fire-EMS.  Further, improved inter-professional collaboration between the 
prehospital staff and ED staff can improve the patient outcomes and facilitate patient 
transition from the prehospital to the hospital setting (Reeves, 2017).  The PHTTP 
demonstrated that prehospital personnel are important in the patient progression through 
emergent evaluation through the inclusion and reliance upon troponin values obtained 
outside the ED as well as the hospital clinical laboratory (Venturini, 2013).  The PHTTP 
preliminary results demonstrated that a prehospital troponin value is reliable and effective 
in decreasing the throughput time of chest pain patients in the ED which would 
concomitantly decrease the time to disposition and utilization of EIS if it is required.  The 
utilization of prehospital personnel to use POC devices to measure troponin levels during 
transport of patients to the ED may result in earlier diagnosis of ACS (Venturini, 2013). 
Moreover, EIS leads to a statistically significant decrease in mortality and refractory 
ischemia (Li, 2017).  Additionally, the PHTTP will reduce healthcare costs by using 
interventions earlier in the patient treatment algorithm and reduce readmissions and 
mitigate adverse outcomes. In fact, readmission costs are $14,300 following discharge 
from an NSTE-ACS events (Patel, 2018).  With early intervention, the re-hospitalization 
rate was decreased by 9% (Meadows, 2012).  The PHTTP can reduce re-hospitalizations 
by 9% by reducing the time to interventional strategies and readmission costs of 
$14,300/event.  Finally, the PHTTP preliminary results improved ED workflow and 
reduced ED overcrowding by decreasing the LOS of chest pain patients that arrive by 
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EMS. EDs in the US are in crisis from overcrowding as it has become the safety net for 
health care (Freibott, 2017).  Therefore, this PHTTP has the potential to create 
sustainable change within the local healthcare environment and if implemented on a 
larger scale will have positive ramifications in the larger health care environment.  
 Key Lessons Learned from Implementation Process 
 Many lessons were learned during the design, recruitment, and implementation of 
the PHTTP: 1) resistance to inter-professional collaboration, 2) financial investment of 
the health care components, and 3) investment in innovation.  Collaboration between 
EMS systems and hospital EDs can often be turbulent and strained and the PHTTP 
required extensive cooperation between these two systems.  Additionally, dealing with 
the administrative structure of one component of the health care system can often be 
taxing, but dealing with the administration of two components concurrently was the real 
challenge.  The investment of financial capital in the current strained health care system 
was a major hurdle to implementation of the PHTTP.  The exploration of grants and 
organizational donations would be beneficial for the implementation of future projects of 
this type that involve more than one health care component.  Even in the contemporary 
evidence-based emergency health care system, barriers still exist against the 
implementation of innovative approaches to established treatment algorithms and many 
systems are uncomfortable in straying from the established norms.  This variation from 
the established norms represented a challenge through the process of this project and 
required greater adaptation than what was previously anticipated. 
Recommendations 
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 The preliminary results of the PHTTP demonstrated a reduction in the time to 
final disposition of chest pain patients suspected of NSTE-ACS that present to the 
Covenant Plainview ED via Plainview Fire-EMS.  The ongoing implementation 
demonstrated a 40.96 minute (0.67 hour) reduction in time to final disposition which 
could create sustainable change is patient outcomes and ED workflow.  Future 
recommendations for this project are as follows: 1) the current PHTTP should be 
continued in the host organizations and additional data obtained, 2) the PHTTP 
Sustainability Plan should be enacted in the host organizations while the additional data 
is obtained, and 3) once adequate sustainability is obtained within the host organizations, 
considerations can be made for project implementation in other organizations. 
. 
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Appendix A.  All-cause Mortality 
 
Mortality Post Discharge NSTE-ACS AMI 
30 day 2.6% 7.99% 
90 day 12.6% 6.1% 
180 day 18.3% 10.2% 
1 year 23.5% 11.5% 
2 year 33.2% 16.4% 
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Appendix B.  Prehospital Troponin Evaluation Table Template 
Used with permission, © 2007 Fineout-Overholt 
 
Citation: 
author(s)
, date of 
publicati
on& title 
Purpose 
of Study 
Conc
eptua
l 
Fram
ewor
k 
Design/ 
Method 
 
Sample/Settin
g 
Major 
Variables 
Studied 
and 
Their 
Definition
s 
 
Measurement 
of Major 
Variables 
Data 
Analysis 
 
Study Findings 
Appraisal of Worth to Practice 
Strength of the Evidence (i.e., level of 
evidence + quality [study strengths and 
weaknesses]) 
RECOMMENDATIONS 
Cantor, 
W., et al. 
Em 
Medicine 
2005; 
16(1), 1-
9. 
 
Evaluate 
PCI 
impact 
None RCT 
 
OPUS 
TIMI-16 
Trial 
 
N= 10,288 in 
10 months 
 
Setting: 
hospitalized 
patient in 29 
countries 
 
Attrition: 
1855 excluded 
due to 
previous PCI 
 
147 had 
STEMI & PCI 
before 
randomization 
IV = EIS 
 
DV1 = OT 
DV2 = PCI 
Event rates 
mortality at 10 
months in OT 
& PCI groups 
Percent 
 
Hazard 
Ratios 
 
Pearson test 
– EIS  & 
OT/PCI 
 
 
PCI is associated 
with lower MACE 
 
MACE st 10 
months was: 1.3% 
(low risk), 2.2% 
(intermediate 
risk), & 11.4% 
(high risk) 
Limitations: 
- Bias: decision to utilize EIS was at the 
discretion of the treating physician 
- some non-fatal outcomes Re-infarction, 
stroke) may have occurred before EIS 
 
Strengths: 
-large sample (8286 after exclusions) 
-identified that EIS effect varies with risk 
stratification 
 
Conclusion: 
-EIS  MACE in high-risk and little 
effect in low-risk 
 
Feasibility:  
-EIS is feasible to implement in high-risk 
patients 
-Benefits outweighs risk in high risk 
patients 
Cox, D., 
et al. Am 
J Card. 
2006; 
149(2): 
275-283 
PCI with 
& 
without 
thrombol
ytics 
reduces 
MACE  
None RCT 
 
STEMI 
& 
NSTEM
I 
randomi
zed 
equally 
into 1 of 
4 
groups: 
-BA+T 
-BA-T 
-SC+T 
-CS-T 
N = 2082 over 
1 year 
 
Setting: 76 
medical 
centers in 9 
countries 
 
Attrition: 36 
lost to 15 year 
follow-up 
 
IV = PRS 
 
DV1 = 
BA+T 
DV2 = 
BA-T 
DV3 = 
CS+T 
DV4 = CS-
T 
15 year 
mortality rate 
was measured 
for all 
intervention 
groups based 
on occurrence 
of MACE 
Percent 
 
ITT 
 
Chi-square 
test for 4-
way 
comparison 
of groups 
 
Survival 
technique 
and log 
rank for 
MACE 
PCI improves 
MACE versus OT 
 
NSTEMI had 
delayed arrival to 
hospital (2.4 
hours) versus 
STEMI (1.8 hours) 
 
1 year NSTEMI 
MACE of 24% 
versus STEMI 
MACE of 16.6% 
Limitations: 
- small sample size for medication 
evaluation 
- retrospective analysis was not included 
in original study design 
 
Strengths: 
-29 center trial 
 
Conclusion: 
-PCI strategies with & without 
thrombolytics are effective in reducing 
MACE 
-delays in intervention lead to > MACE 
for NSTEMI 
 
Feasibility: 
-reasonable to implement into ED practice 
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-benefits of MACE outweighs risk of 
both PCI & thrombolytics 
 
Ezekowit
z, J., et al. 
JAHA, 
2015; 
4(12): 1-
11 
 
PTT 
accelerat
es TTD 
None RCT 
 
PROAC
T-4 was 
a 
prospecti
ve, 
open-
label, 
blinded-
endpoint 
(PROBE
). 
Patients 
were 
randomi
zed in 
the 
prehospi
tal 
setting 
1:1 into 
POCT or 
UC 
groups.  
 
 
N = 601 in 19 
months 
UC=296 
POCT=305 
 
Setting: 25 
ambulances in 
Edmonton, 
Alberta, 
Canada 
 
Attrition:  
UC=2 –
withdrew 
consent 
 
POCT=57 – 
55 no POCT 
result & 2 
withdrew 
consent 
IV = PTT 
 
DV1 = 
POCT 
DV2 = 
TTD 
+POCT > 0.03 
ng/mL 
Prehospital 
 
+POCT > 0.01 
ng/mL 
Hospital 
 
TTD = FMC to 
FD measured 
in hours 
ITT 
Analysis 
 
Per 
Protocol 
Analysis 
 
2 sided 
statistical 
tests with 
5% level of 
significance 
0.29 reduction in 
TTD 
 
POCT = 38 
minutes 
UC = 139 minutes 
 
POCT TTD = 8.8 
hrs (P=0.069; 
Padjusted=0.074)  
UC TTD = 9.0 hrs 
(P=0.05; 
Padjusted=0.059)  
Sensitivity of 
POCT=44%, 
specificity=96%, 
positive predictive 
value=73.3%, and 
negative predictive 
value=87.2% 
 
 
 
Strength: in a less-advanced EMS 
systems, or greater distances or durations 
of EMS transport, there may be an even 
greater magnitude of the effect than 
observed in this study 
Weakness: 18% device failure with no 
POCT results and patients, EMS personnel 
and physicians treating the patient were 
aware of the allocated arm  
Conclusion: POCT prehospital troponin 
testing resulted in 0.29 hour reduction in 
time to TTD 
Feasibility: this intervention is feasible to 
implement into practice and has potential 
for even greater positive results in longer 
transport scenarios. Risk to patients is 
minimal and benefit outweighs risk. 
 
Than, M., 
et al, 
JAMA 
2013; 
4(12): 1-
11 
Utilize 
ADP 
without 
increasin
g MACE 
None RCT 
 
Randomi
zed 1:1 
to APD 
and UC 
N = 544 in 19 
months 
 
ADP=271 
UC=273 
 
Setting: 
Christchurch 
Hospital ED 
in 
Christchurch, 
New Zealand 
 
Attrition: 
UC-1 
ADP=1 
withdrew 
consent 
IV1 = ADP 
IV2 = SCP 
 
IV1 = hs-
cTn 
IV2 = SD 
IV3 = 
MACE 
hs-cTn < 0.03 
ng/mL 
 
SD < 2 hours 
 
MACE 
standard 
classification 
ITT 
 
Chi-square 
 
Odds ratio 
 
Percentage 
ADP doubled the 
proportion of 
patient with early 
discharge 
 
19.3% of ADP 
patients 
discharged by 6 
hours 
11% of UC 
patients 
discharged in 6 
hours 
 
52 of 270 patients 
in the 
experimental 
group were 
Limitations: 
-single center trial  generalizability & 
limited sample size 
-cannot exclude small differences in risk 
of MACE 
 
Strengths: 
-safety of ADP was demonstrated in 1975 
patients 
 
Conclusion:  
-Trial demonstrated that the experimental 
pathway is an effective and practical 
strategy to improve early discharge rates 
for some patients with chest pain.  
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successfully 
discharged within 
6 hours compared 
with 30 of 272 
patients in the 
control group 
(19.3% vs 11.0%; 
odds ratio, 1.92; 
95% CI, 1.18-
3.13; P = .008)  
 
 
 
Feasibility:  
- ADP is feasible to facilitate early 
discharge 
-Benefits of utilizing ADP outweigh 
calculated risks of MACE in chest pain 
patients 
 
Wallentin
, L., et al. 
Lancet 
2016; 
388(1005
4:1903-
1911 
EIS 
reduces 
MACE 
None RCT 
 
Prospect
ive, 
randomi
zed, 
open and 
double-
blind, 
placebo-
controlle
d study 
with 
parallel 
groups 
 
Patients 
randomi
zed to 
EIS or 
non-EIS 
N = 2457 in 
22 months 
 
Setting: 58 
Scandinavian 
Hospitals in 
Sweden, 
Denmark, & 
Norway 
 
Attrition: 36 – 
death & loss 
to follow-up 
for unknown 
reason 
IV = EIS 
 
DV1 = PCI 
DV2 = 
MACE 
PCI – met 
criteria or did 
not meet 
criteria for 
cardiac 
catherization; 
upper limit of 
normal 
Mean Gain 
Analysis 
 
Regression 
analysis 
 
Odds ratio 
 
Hosemer-
Lemeshow 
Test 
PCI reduced 
MACE by a mean 
of 549 days at 2 
years 
 
PCI postponed 
MACE by average 
of 18 months and 
readmission by 37 
months compared 
to UC 
 
PCI postponed 
MACE by 1128 
days (95% CI 830-
1366) 
More than 5 
factors for 
invasive strategy 
reduced mortality 
from 15.4% (20 of 
130) to 5.2% (7 of 
134) (risk ratio 
(RR) 0.34, 95% 
confidence 
interval (CI) 0.15 
to 0.78, p = 0.006) 
Death/MI was also 
reduced in patients 
with 3–4 factors 
from 15.7% (80 of 
511) to 10.8% (58 
of 538) (RR 0.69, 
Limitations: 
-bias towards selection of medium to high 
risk patients limiting applicability to low 
risk. 
-confined to Scandinavian patients with 
limited prior revascularization 
-only risk factors present on admission 
were included – excluding factors that 
developed during hospitalization 
 
Strengths: 
-15 year follow-up 
 
Conclusion: 
-PCI reduced occurrence of MACE events 
over 15 years 
 
Feasibility: 
-feasible to implement protocol to 
accelerate time to EIS 
-benefits of EIS( MACE) outweigh risks 
(cardiac arrhythmias, bleeding, vessel 
perforation) 
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95% CI 0.50 to 
0.94, p = 0.02)  
 
 
Cullen, 
L., et al. 
JACC, 
Lancet 
2013; 
62(14): 
1242-
1249 
Validate 
POCT 
None Prospect
ive 
Cohort 
 
2 
cohorts: 
-ADAPT  
-APACE 
N = 2885 
 
Setting: 2 
urban ED in 
Brisbane, 
Australia & 
Christchurch, 
New Zealand 
 
Attrition: 
-ADAPT: 
TIMI 
incomplete or 
no stored 
serum (341) 
-APACE: 
CP not ACS 
of hs-cTnT 
above cut-
off(46); no 
stored 
serum(655; no 
ECG(6) 
IV = hs-
cTn 
 
DV1 = 
MACE 
DV2 = 
TIMI 
MACE = any 
 
TIMI < 1 
Chi-square 
analysis 
 
McNemar 
analysis 
ADP protocol 
reduced 30 day 
MACE by 40% 
 
ADAPT = 15.1% 
of MACE st 30 
days 
 
APACE = 17.1% 
MACE at 30 days 
Limitations: 
-applicability of risk limited to CP patient 
and excludes atypical presentations 
-most were Caucasian limiting 
generalizability 
 
Conclusion: An early-discharge strategy 
using an hs-TnI assay and TIMI score < 1 
is safe and has the potential to decrease 
the observation periods and admissions for 
approximately 40% of patients with 
suspected ACS  
Feasibility: 
-applicable to integration into practice in 
the ED to reduce TTD 
-Benefits of reducing TDD has limited 
risk of MACE 
Meek, R., 
et al. Em 
Med Aus. 
2016; 
28(3): 
279-286 
Evaluate 
ADP in 
reducing 
MACE 
and ED 
discharg
e 
None Prospect
ive 
Cohort 
 
  
N = 1547 in 
54 days 
 
Setting: 3 
Montash 
Health ED in 
Clayton, 
Victoria, 
Australia & 
Dandenong, 
Victoria, 
Australia 
 
Attrition: 
No follow-up 
= 114 
IV = ADP 
 
DV = 
MACED 
MACED = 
successful 
discharge 
Percentage ADP supports safe 
early discharge 
 
MACED = 
(0.09%, 95% CI 
0.002–0.5)  
 
UC = (0.3%, 95% 
CI 0.08–0.8)  
 
Limitations: 
-subjective physician selection of eligible 
patients 
 
Conclusions: 
- The ADP supports safe, early discharge 
of low-risk chest pain patients from the 
ED.  
Feasibility: 
- the use of and ADP is a safe method of 
ED discharge of chest pain patients 
- ADP demonstrated limited risk of 
MACE  
Stengaard
, C., et al. 
ACC, 
2013;112 
Evaluate 
POCT in 
identifyi
ng ACS 
None Observat
ional 
Prospect
N = 985 in 19 
months 
 
IV = 
POCT 
protocol 
 
POCT > 50 
ng/L 
Percentage 
 
Chi-square 
test 
Prehospital 
quantitative POCT 
was statistically 
successful 
Limitations: 
-inclusion in the study at the discretion of 
the paramedics creating potential selection 
bias 
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(9): 1361-
1366 
and 
reducing 
MACE 
ive 
Cohort  
 
Patients 
with CP 
< 70 
minutes 
in 
duration 
Setting: 
ambulances in 
Central 
Denmark 
 
Attrition: 
-12 lost to 
follow-up 
DV = 
+POCT 
 
 
Kurskal-
Wallis Test 
 
1-way 
sample t-
test 
 
2-
proportion 
Z-test 
 
Diagnostic 
accuracy of POCT 
values was 0.67 
 
+prehospital 
POCT troponin = 
MACE of 23%/yr 
 
-prehospital POCT 
MACE = 5%/yr 
-baseline data retrieved from incomplete 
databases 
 
Strengths: 
-demonstrated adequate correlation of 
prehospital POCT results 
 
Conclusions: 
-large-scale quantitative prehospital POC-
cTnI testing by paramedics is feasible  
Feasibility: 
-is applicable to utilization of prehospital 
troponin testing protocol 
Venturini, 
J., et al. 
Prehosp 
Em Care, 
2013; 17: 
89-91 
Validate 
POCT in 
ambulan
ce versus 
EDT 
None Observat
ional  
Cohort 
 
EMS 
Cohort 
 
Hospital 
Cohort 
N= 42 in 60 
days 
 
Setting: 
Loyola 
University 
Hospital & 
EMS in 
Maywood, 
Illinois 
 
Attrition: 3 – 
1 cartridge 
error & 2 
interfering 
substances 
IV = PTT 
 
DV1 = 
POCT 
DV2 = 
EDT 
POCT in 
ng/mL 
 
EDT in ng/mL 
Intra-class 
correlation 
POCT in moving 
ambulance 
provided accurate 
results 
 
coefficient 0.997; 
95% confidence 
interval 0.994 to 
0.998; p < 0.005  
 
Limitations: 
-small sample size 
-devices were not subject to normal 
adverse conditions 
-device had 7.2% failure rate 
Strengths: 
-results were highly correlated 
 
Conclusions: 
- When used in a moving ambulance, the 
i-STAT point- of-care device reliably 
provided accurate results of troponin 
assays when compared with the results of 
those performed in the ED  
Feasibility: 
-applicable to the practice of prehospital 
troponin testing 
Darling, 
C., et al. 
Clin Epi. 
2013; 5: 
229-236 
Evaluate 
MACE 
after 
ACS 
None Descripti
ve Study 
 
Reviewe
d 
medical 
records 
of 
residents 
of 
Worcest
er, MA, 
USA 
metropol
itan area 
hospitali
zed at 
eleven 
N = 3762 in 
2001, 2003, 
2007, & 2007 
 
Setting: Data 
from 
Worcester 
Heart Attack 
Study 
(WHAS) in 
Massachusetts 
 
Attrition: 
-NA 
IV = ACS 
 
DV = 
MACE 
 Percentages Post discharge 
MACE was higher 
for NSTEMI than 
STEMI 
 
NSTEMI MACE: 
-90 days=12.6% 
-1 years=23.5% 
-2 years=33.2% 
 
STEMI MACE: 
-90 days=6.1% 
-1 year=11.5% 
-2 years=16.4% 
 
STEMI were 
significantly more 
likely to have 
Limitations: 
-primary Caucasian limits generalizability 
-non-randomized 
 
Strengths: 
-large sample size N=3762 
 
Conclusions: 
- patients with STEMI experienced a 
better post-discharge prognosis than those 
with NSTEMI  
Feasibility: 
-provides validity to the assertion that 
NSTEMI patients are at higher risk for 
MACE and an intervention is needed to 
mitigate this risk 
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central 
Massach
usetts 
medical 
centers 
for acute 
myocard
ial 
infarctio
n (AMI) 
during 
2001, 
2003, 
2005, 
and 
2007  
 
survived at 3 
months (OR 1.38; 
95% CI 1.01–
1.87), 1 year (OR 
1.38; 95% CI 
1.09–1.74), and 2 
years (OR 1.53; 
95% CI 1.23–
1.89) (all P-values 
,0.05)  
NSTEMI were 
significantly more 
likely to have died 
during the years 
under study than 
patients with 
STEMI (adjusted 
HR = 1.28; 95% 
CI 1.14–1.44) (P-
value ,0.05)  
 
 
ACS-Acute Coronary Syndrome; ADAPR-Accelerated Diagnostic Protocol to Assess Patients with Chest pain with Troponin; ADP-Accelerated Diagnostic Protocol; APACE-
Advantageous Predictors of Acute Coronary Syndromes Evaluation; BA+T-Balloon Angioplasty w/Thrombolytics; BA-T-Balloon Angioplasty w/o Thrombolytics; CS+T-Cardiac 
Stent w/Thrombolytics; CS-T-Balloon Angioplasty w/o Thrombolytics; EDT-Emergency Department Troponin; EIS-Early Invasive Strategy; EMS-Emergency Medical Services; 
FMC-First Medical Contact; FD-Final Diagnosis; hs-cTn-high-sensitivity Troponin; ITT-Intention to Treat; MACE-Major Adverse Cardiac Events; MACED-MACE with ED 
Discharge; NSTEMI-non-ST segment Elevation Myocardial Infarction; OT-Oral Thrombolytics; PCI-Percutaneous Cardiac Intervention; POCT-Point-of-Care Troponin; PRS-
Prehospital Stratification; PTT-Prehospital Troponin Testing; RPD-Rapid Diagnostic Pathway; SD-Successful Discharge; STEMI-ST-segment Elevation Myocardial Infarction; TIMI-
Thrombolysis in Myocardial Infarction; TTD-Time to Final Diagnosis; UC-Usual Care; 
 
 Appendix C.  Search Results Synthesis Table 
 
DATABASE CINAHL     COCHRAN   PUBMED         
  KEYWORD TITLE SUBJECT COMBO: KEYWORD MESH MESH MAJOR TITLE/ TITLE MESH 
SEARCH TERM       TI/AB/KW   TERMS TOPIC ABSTRACT   TITLE 
Acute Coronary Syndrome 3956 2292 1291 4455 3128 22646 25079 14051 6207 11609 
ACS 1859 0 162 2542 2 25079 2006 12319 976 717 
non-ST segment elevation myocardial 
infarction 
339 0 0 947 456 2006 1744 990 347 1454 
NSTEMI 195 0 23 289 0 1744 1457 1382 111 163 
non-ST segment acute coronary syndrome 315 0 66 727 321 1457 695 465 244 1679 
NSTE-ACS 98 0 4 245 0 695 2205 695 45 0 
Troponin 2377 1874 832 2638 2064 14627 14627 12523 5023 10672 
High Sensitivity Troponin 327 0 130 418 21 2205 2205 493 250 1817 
Prehospital Troponin 118 35 0 190 146 431 431 16 13 342 
Point of Care Troponin 15 7 0 14 11 48 48 44 13 31 
Early Invasive Strategies 212 0 7 1289 439 9018 9018 56 2 8352 
EIS 216 0 4 106 2 1129 1129 929 70 0 
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Appendix D.  Study Methodology Synthesis Table 
 
  1 2 3 4 5 6 7 8 9 10 11 12 
Troponin 
Isotype 
NS NS cTn cTnT cTnI cTnI cTnT cTnI Both cTn cTnT cTnT 
Troponin 
Sensitivity 
NS NS Standard High Standard Standard High High High NS High Standard 
Analysis Setting NS IPH Lab ED PH PH/ED/IPH ED/IPH ED ED PH ED PH & ED 
Inclusion 
Criteria 
NS NSTEMI Typical 
Chest 
Pain 
Typical 
Chest 
Pain 
Typical 
Chest Pain 
Typical 
Chest Pain 
Typical &  
Atypical 
Chest Pain 
Typical 
Chest Pain 
Typical 
Chest 
Pain 
Typical 
Chest 
Pain 
Typical & 
Atypical 
Chest Pain 
Typical 
Chest Pain 
Exclusion 
Criteria 
NS STEMI NS STEMI, 
CA 
STEMI, 
Trauma, 
Syncope, 
CNS, CA, 
VT, 
AFRVR 
Syncope, 
dyspnea, 
AMS 
< 1 value 
below 99% 
URL 
Pregnancy, 
< 18 yrs, 
terminal 
illness, 
inter-
facility 
transfer 
< 18 yrs, 
symptoms 
> 12 hrs, 
CKD 
Atypical 
Chest 
Pain 
Symptom 
onset > 6 
hours 
Symptom 
onset > 70 
minutes 
Analysis Interval NS NS Variable 3-4 hrs 15 minutes NS up to 6 hr 2 hr 0,1,2,3, & 
6 hrs 
NS 0,2,4, & 6 
hrs 
0 & 2 hrs 
Assay Range 
Cut-off 
NS NS 99% 
URL 
99% 
URL 
99% URL NS 99% URL 99% URL 99% URL NS 99% URL 99% URL 
1 = Amsterdam, E., et al. (2014), 2 = Khera, S., et al. (2014), 3 = Layfield, C., et al (2015), 4 = Ezokowitz, J, et al. (2015), 5 = Venturini, J, et al. (2013), 6 = Borna, C., et al. (2016), 7 = 
Bierner, M., et al, (2015), 8 = Cullen, L, et al, (2013), 9 = Gimenez, M, et al. (2014), 10 = Ishak, M, et al. (2015), 11 = Saad, Y, et al. (2015), 12 = Stengaard, C, et al. (2013). 
 
 
AMI-Acute Myocardial Infarction, AMS-Altered Mental Status, AFRVR-Atrial Fibrillation with Rapid Ventricular Response, CA-Cardiac Arrest, cTn-
Cardiac Troponin Unspecified, cTnI-Cardiac Troponin I, cTnT-Cardiac Troponin T, CKD-Chronic Kidney Disease, CNS-Central Nervous 
Symptomology, ED-Emergency Department, IHP-In-patient Hospitalization, PH-Pre-hospital, NS-Not Specified, NSTEMI-non-ST Segment Elevation 
Myocardial Infarction, STEMI-ST Segment Elevation Myocardial Infarction, URL-Upper Reference Limit, VT-Ventricular Tachycardia 
 
 
 Appendix E.  Levels of Evidence Synthesis Table 
 
  
LEVELS OF EVIDENCE 1 2 3 4 5 6 7 8 9 10 
Level I: Systematic review or meta-analysis 
   
              
Level II: Randomized Controlled Trial  X X  X  X 
 
       X   
Level III: Controlled Trial without 
Randomization 
          
 
        
Level IV: Case-control or Cohort Study         X   X X 
 
X 
Level V:  Systematic Review of Qualitative or 
Descriptive Studies 
           X         
Level VI: Qualitative or Descriptive Study                     
 
1 = Amsterdam, E., et al. (2014), 2 = Khera, S., et al. (2014), 3 = Layfield, C., et al (2015), 4 = Ezokowitz, J, et al. (2015), 5 = Venturini, J, et al. (2013), 6 = Borna, C., et al. (2016), 7 = 
Bierner, M., et al, (2015), 8 = Cullen, L, et al, (2013), 9 = Gimenez, M, et al. (2014), 10 = Ishak, M, et al. (2015), 11 = Saad, Y, et al. (2015), 12 = Stengaard, C, et al. (2013). 
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Appendix F.  Outcome Measures Synthesis Table  
 FMC to T1 T1 to T2 T2 to Dx FMC to Dx Dx to EIS MACE 
1 ⎯ ⎯ ⎯    
2 ⎯ ⎯     
3  ⎯    ⎯ 
4 ⎯ ⎯  ⎯   
5       
6       
7 ⎯ ⎯ ⎯    
8      ⎯ 
9      ⎯ 
10  ⎯ ⎯    
FMC = First Medical Contact, T! = First Troponin, T2 = Second Troponin, Dx = Diagnosis, EIS = Early Invasive Strategy, MACE = Major Adverse Cardiac Events 
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Appendix G.  Lippitt’s Change Theory 
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Appendix H.  Prehospital Troponin Logic Model 
 
